# EDGAR Filing Document

**Accession Number:** 0001106861
**File Stem:** 0001214659-25-013498
**Filing Date:** 2025-9
**Character Count:** 184855
**Document Hash:** b854ba421f615f5b18a3ca100cd957ec
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001214659-25-013498.hdr.sgml**: 20250909

**ACCESSION NUMBER**: 0001214659-25-013498

**CONFORMED SUBMISSION TYPE**: 10-12G/A

**PUBLIC DOCUMENT COUNT**: 7

**FILED AS OF DATE**: 20250909

**DATE AS OF CHANGE**: 20250909

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CS DIAGNOSTICS CORP.
- **CENTRAL INDEX KEY:** 0001106861
- **STANDARD INDUSTRIAL CLASSIFICATION:** SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 201290331
- **STATE OF INCORPORATION:** WY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-12G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-29611
- **FILM NUMBER:** 251301581

**BUSINESS ADDRESS:**
- **STREET 1:** STRESEMANNALLEE 4B
- **CITY:** NEUSS
- **STATE:** 2M
- **ZIP:** 41460
- **BUSINESS PHONE:** 49 21311510871

**MAIL ADDRESS:**
- **STREET 1:** STRESEMANNALLEE 4B
- **CITY:** NEUSS
- **STATE:** 2M
- **ZIP:** 41460

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FLASHZERO CORP.
- **DATE OF NAME CHANGE:** 20221108

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHILDRENS INTERNET INC
- **DATE OF NAME CHANGE:** 20030205

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DWC INSTALLATIONS
- **DATE OF NAME CHANGE:** 20000214

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

 **Amendment No. 1** 

**FORM 10**

**GENERAL FORM FOR REGISTRATION OF SECURITIES**

**Pursuant to Section 12(g) of The Securities Exchange Act of 1934**

![](cscorp_logo.jpg)

**CS DIAGNOSTICS CORP.**

(Exact name of registrant as specified in its charter)

Wyoming 20-1290331 <br> (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.)

Stresemannallee 4b Neuss, Germany 41460

(Address of principal executive offices)

+49 (0)2131 151 08 71

(Issuer's telephone number)

Securities registered pursuant to Section 12(b) of the Act: Not Applicable

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $0.001 per share

Indicate by check mark whether the registrant is a large accelerated ﬁler, an accelerated ﬁler, a non-accelerated ﬁler, a smaller reporting company, or an emerging growth company. See the deﬁnitions of "large accelerated ﬁler," "accelerated ﬁler," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer □ Accelerated filer □ <br> Non–Accelerated filer □ Small reporting company ⌧ <br> Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised ﬁnancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10**

Certain information required to be included herein is incorporated by reference to specifically-identified portions of the body of the information statement filed herewith as Exhibit 99.1. None of the information contained in the information statement shall be incorporated by reference herein or deemed to be a part hereof unless such information is specifically incorporated herein by reference.

**Item 1. Business.**

The information required under this item is contained under the sections of the information statement entitled "Business," "Risk Factors," "Security Ownership," and "Capitalization." Those sections are incorporated herein by reference.

**Item 1A. Risk Factors.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors" and "MD&A." Those sections are incorporated herein by reference.

**Item 2. Financial Information.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Description of Capital Stock," and "Capitalization—Management's Discussion and Analysis of Financial Condition and Results of Operation" and the financial statements referenced therein, of the Information Statement which sections are incorporated herein by reference.

**Item 3. Properties.**

The information required under this item is contained under the section of the information statement entitled "Business—Leased Offices." Those sections are incorporated herein by reference.

**Item 4. Security Ownership of Certain Beneficial Owners and Management.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," and "Capitalization." Those sections are incorporated herein by reference.

**Item 5. Directors, Executive Officers and Corporate Governance.**

The information required under this item is contained under the section of the information statement entitled "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," and "MD&A" Those sections are incorporated herein by reference.

**Item 6. Executive Compensation.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Executive Compensation," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 7. Certain Relationships and Related Transactions, and Director Independence**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance—Stock and Stock Option Issuances in 2023 and 2024 and Related Party Transactions," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 8. Legal Proceedings.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors" and "Legal Proceedings." Those sections are incorporated herein by reference.

**Item 9. Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters.**

The information required under this item is contained under the section of the information statement entitled "Business," "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 10. Recent Sales of Unregistered Securities.**

The information required under this item is contained under the section of the information statement entitled "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Related Party Transactions," "Description of Capital Stock—Recent Issuances of Securities," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 11. Description of Registrant's Securities to be Registered.**

The information required under this item is contained under the section of the information statement entitled "Business—Overview," "Risk Factors," "Security Ownership," "Directors, Executive Officers, and Corporate Governance," "Description of Capital Stock," "Capitalization," and "MD&A." Those sections are incorporated herein by reference.

**Item 12. Indemnification of Directors and Officers.**

The information required under this item is contained under the section of the information statement entitled "Business," "Risk Factors," "Directors, Executive Officers, and Corporate Governance—Limitation of Liability and Indemnification," and "MD&A." Those sections are incorporated herein by reference.

**Item 13. Financial Statements and Supplementary Data.**

The information required under this item is contained under the section of the information statement entitled "Index to Financial Statements." This section is incorporated herein by reference.

**Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.**

None.

**Item 15. Financial Statements and Exhibits.**

(a) Financial Statements. The information required under this item is contained under the section of the information statement entitled "Index to Financial Statements." This section is incorporated herein by reference.

(b) Exhibits. The following documents are filed as exhibits hereto:

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Exhibit Description</u>** |
| 1.1 | Amended Financial period ending March 31, 2025 |
| 99.1 | Information Statement |

---

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: September 8, 2025 | **CS Diagnostics Corp.** | **CS Diagnostics Corp.** |
|  | By: | /s/Mohammad EsSayed |
|  |  | Mohammad EsSayed |
|  |  | Group CFO, VP |

---

## Exhibit 1.1

**Exhibit 1.1**

![](cs1_1logo.jpg)

CS DIAGNOSTICS CORP. OTCQB-

CSDX

INDEX TO FINANCIAL STATEMENTS

---

| |
|:---|
| Balance Sheets as of March 31, 2025, and December 31, 2024 |
| Statements of Operations for the Three months period ended March 31, 2025, and March 31, 2024 |
| Statements of Stockholders' Equity for Three months period ended March 31, 2025, and March 31, 2024 |
| Statements of Cash Flows for the Three months period ended March 31, 2025, and March 31, 2024 |
| Notes to the Financial Statements |

---

![](cs1_1logo.jpg)

---

| |
|:---|
| **CS DIAGNOSTICS CORP. CSDX** |
| <br> **BALANCE SHEET FOR THE PERIOD ENDED March 31 2025** |

---

---

| | | |
|:---|:---|:---|
|  | **March 31, 2025** | **December 31, 2024** |
|  | *Un-Audited* | *Audited* |
| ***Assets*** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>**Current Assets** <br>|  |  |
| Cash | 51386 | 501 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Receivables | 54726 |  |
| **Total Current Assets** | $**106112** | $**501** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible Assets | 499400000 | 499400000 |
| **Total Assets** | $**499506112** | $**499400501** |
| **Liabilities and Stockholders' Deficit** |  |  |
| **Current Liabilities** |  |  |
| Account Payables | 2931 | 1428 |
| Non-current liabilities  | 72000 |  |
| **Total Liabilities** | $**74931** | $**1428** |
| **Shareholder's Deficit** |  |  |
| Common stock, $0.00001 par value; 250,000,000 shares authorized,137,340,200 shares issued and outstanding as of March 31, 2025 | 1373 | 1373 |
| &nbsp;&nbsp;&nbsp;Preferred stock Series A, $0.00001 par value;5,000 shares authorized, 10 shares issued and outstanding as of March 31, 2025 |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock Series B, $0.00001 par value; 20,000,000 shares authorized, 19,992,575 shares issued and outstanding as of March 31, 2025 | 2000 | 2000 |
| &nbsp;&nbsp;&nbsp;Preferred stock Series C, $0.00001 par value; 4,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2025 | 40 |  |
| Additional paid-in capital | 504163629 | 504163629 |
| Accumulated deficit | (4735861) | (4767928) |
| **Total Stockholders' Deficit** | $**499431181** | $**499399073** |
| **Total Liabilities and Stockholders' Deficit** | $**499506112** | $**499400501** |

---

*The accompanying notes are an integral part of these financial statements.* 

*This is an unaudited financial statement, can be subject to minor changes upon Auditor review*![](cs1_1logo.jpg)

---

| |
|:---|
| **CS DIAGNOSTICS CORP.** |
| **STATEMENT OF OPERATIONS** |
| **FOR THE PERIOD ENDED March 31, 2025** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31<sup>st</sup>** | **For the Three Months Ended March 31<sup>st</sup>** |
|  | **2025** | **2024** |
| Revenue  | 70420 | 53258 |
| **Revenue** | $**70420** | $**53258** |
| *Operating Expenses* |  |  |
| Professional Fee | 16519 | 44555 |
| General & Administrative Expenses  | 21834 | 140 |
| Total Operating expenses | 38353 | 8564 |
| **Income/(loss) from Operations** | $**32067** | $**8564** |
| Other Income / (Expense) |  |  |
| Debt Written off |  |  |
| Net Income / (loss) | $32067 | $0.00 |
| Basic and diluted loss per share | 0.00 | 0.00 |
| **basic and diluted loss weighted average shares** | **137340200** | **110790200** |

---

*The accompanying notes are an integral part of these financial statements.* 

*This is an unaudited financial statement, can be subject to minor changes upon Auditor review*![](cs1_1logo.jpg)

---

| |
|:---|
| **CS DIAGNOSTICS CORP.** |
| **STATEMENT OF STOCKHOLDERS (DEFICIT)** |
| **FOR THE PERIOD ENDED March 31, 2025** |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock B** | **Preferred Stock B** | **Preferred Stock C** | **Preferred Stock C** | **Common Stock** | **Common Stock** | **Additional** | **Accumulated** | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Paid-in Capital** | **Deficit** | **Total** |
| Balance, January 1, 2024 | 20000000 | $2000 | $0 | $0 | 110790200 | $1018 | $504173122 | $(4798689) | $449407450 |
| Reversed Stock Split |  |  |  |  |  |  |  |  |  |
| Shares Issued/Converted | (1325) | $0 | $0 | $0 | 26500000 | $355 | $(9493) |  | $(9138) |
| Net income (loss) for the year |  |  |  |  |  |  |  | $761 | $761 |
| **Balance, December 31, 2024** | **19998675** | $**2000** | $**0** | $**0** | **137290200** | $**1373** | $**504163629** | $**(4767928)** | $**449399073** |
| Balance, January 1st, 2025 | 19998675 | 2000 | 0 | 0 | 137290200 | 1373 | 504163629 | (4767928) | 449399073 |
| Shares Issued/Converted | (6100) |  | 4000000 | $40 | 50000 |  |  |  |  |
| Net income (loss) for the period ended March 31, 2025 |  |  |  |  |  |  |  | $32067 | $32067 |
| Shares Issued in acquisition of Assets |  |  |  |  |  |  |  |  |  |
| **Balance, March 31, 2025** | **19992575** | **2000** | **4000000** | **40** | **137340200** | **1373** | **504163629** | **(4735861)** | **449431181** |

---

*The accompanying notes are an integral part of these financial statements.* 

*This is an unaudited financial statement, can be subject to minor changes upon Auditor review*![](cs1_1logo.jpg)

---

| |
|:---|
| **CS DIAGNOSTICS CORP.** |
| **STATEMENT OF CASH FLOWS** |
| **FOR THE PERIOD ENDED March 31, 2025** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31<sup>st</sup>**  | **For the Three Months Ended March 31<sup>st</sup>**  |
|  | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| &nbsp;&nbsp;&nbsp;Net profit/ (loss) | 32067 | 8564 |
| Adjustment to reconcile net loss to net cash used in operating activities |  |  |
| Changes in assets and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Other Receivables | 21750 |  |
| &nbsp;&nbsp;&nbsp;Account payables | (2931) | (11248) |
| **Net cash used in operating activities** | $**50886** | $**(2684)** |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Intangible Asset |  |  |
| **Net cash provided by Investing activities** | **0** | **-** |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;Additional Capital Paid Up |  |  |
| &nbsp;&nbsp;&nbsp;Loan forgiven |  |  |
| **Net cash provided by financing activities** | **0** | **-** |
| &nbsp;&nbsp;&nbsp;Net increase /(decrease) in cash | 50886 | (2684) |
| &nbsp;&nbsp;&nbsp;Cash beginning of period | 501 | 20363 |
| **Cash end of period** | $**51387** | $**17679** |

---

*The accompanying notes are an integral part of these financial statements.* 

*This is an unaudited financial statement, can be subject to minor changes upon Auditor review*

## Exhibit 99.1

**Exhibit 99.1**

![](cscorp_logo.jpg)

CS DIAGNOSTICS CORP.

**State of Incorporation:** Wyoming<br> **I.R.S. Employer Identification No.:** 20-1290331<br> **Principal Executive Offices:**<br> Stresemannallee 4b, Neuss 41460, Germany +49 21311510871

www.csdcorp.us info@csdcorp.us

**Securities to be registered pursuant to Section 12(b):** None<br> **Securities to be registered pursuant to Section 12(g):** Common Stock, $0.00001 par value

1 www.csdcorp.us

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **FORWARD-LOOKING STATEMENTS** | **4** |
| **Business** | **4** |
| &nbsp;&nbsp;&nbsp;Overview | 4 |
| &nbsp;&nbsp;&nbsp;Corporate History | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Parent Company: CS Diagnostics Pharma GmbH* | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Affiliated Companies* | 6 |
| &nbsp;&nbsp;&nbsp;Flagship Product | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CS Protect-Hydrogel | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MEDUSA (Long-Acting Disinfectant) | 6 |
| &nbsp;&nbsp;&nbsp;Leased Offices | 9 |
| **RISK FACTORS** | **9** |
| &nbsp;&nbsp;&nbsp;Risks Related to the Company | 9 |
| &nbsp;&nbsp;&nbsp;Risks Related to Business Operations | 10 |
| &nbsp;&nbsp;&nbsp;Risks Associated with the Pharmaceutical Industry | 15 |
| &nbsp;&nbsp;&nbsp;Risks Related to being a Publicly Traded Company | 17 |
| **SECURITY OWNERSHIP** | **20** |
| &nbsp;&nbsp;&nbsp;Beneficial Owners and Management | 20 |
| **DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE** | **18** |
| &nbsp;&nbsp;&nbsp;Directors and Officers | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thomas Fahrhoefer | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mohammad EsSayed | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sabrina Kummer Godehardt | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Janel Luzana | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mahmoud A. Al-Sayyed | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr. Ralf Herwig | 19 |
| &nbsp;&nbsp;&nbsp;Executive Compensation | 22 |
| &nbsp;&nbsp;&nbsp;Limitation of Liability and Indemnification | 23 |
| &nbsp;&nbsp;&nbsp;Stock and Stock Option Issuances in 2023 and 2024 | 24 |
| &nbsp;&nbsp;&nbsp;Related Party Transactions | 25 |
| **DESCRIPTION OF CAPITAL STOCK** | **26** |
| &nbsp;&nbsp;&nbsp;Common Stock | 26 |
| &nbsp;&nbsp;&nbsp;Preferred Stock | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series A Preferred Stock | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series B Preferred Stock | 26 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series C Preferred Stock | 27 |
| &nbsp;&nbsp;&nbsp;Recent Issuances of Securities | 27 |
| **CAPITALIZATION** | **29** |
| **Management's Discussion and Analysis of Financial Condition and Results of Operation (MD&A)** | **30** |

---

2 www.csdcorp.us

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;Overview and Business Summary | 30 |
| &nbsp;&nbsp;&nbsp;Results of Operations | 30 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fiscal Year 2024 Compared to 2023 | 30 |
| &nbsp;&nbsp;&nbsp;Quarter Ended March 31, 2025 Compared to March 31, 2024 | 31 |
| &nbsp;&nbsp;&nbsp;Liquidity and Capital Resources | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital Structure and Cash Position | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash Burn and Going Concern | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing Plans | 32 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital Expenditures and Requirements | 33 |
| &nbsp;&nbsp;&nbsp;Critical Accounting Estimates and Judgments | 33 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other areas of significant accounting judgment include: | 34 |
| &nbsp;&nbsp;&nbsp;Known Trends, Events, and Uncertainties | 34 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Approval and Commercialization Timeline | 35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Product Launch and Manufacturing | 35 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market Adoption and Competition | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Commercial Potential vs. Risks | 36 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diversification and Other Products | 37 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management and Organizational Changes | 37 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Macroeconomic and Market Conditions | 37 |
| &nbsp;&nbsp;&nbsp;Conclusion | 37 |
| &nbsp;&nbsp;&nbsp;The path forward for CS Diagnostics Corp. presents opportunities as well as significant uncertainties. The Company is in the process of developing CS Protect-Hydrogel, which it believes may represent a novel approach in the medical device space, along with MEDUSA, a long-acting disinfection product. Neither product has received marketing authorization in the United States, and there can be no assurance that regulatory approval will be obtained in a timely manner, or at all. | 37 |
| &nbsp;&nbsp;&nbsp;Like many emerging growth companies, CS Diagnostics faces challenges including obtaining required regulatory approvals, scaling up manufacturing and sales, securing adequate financing, and competing with established industry participants, all while transitioning into an SEC-reporting company subject to enhanced disclosure and compliance requirements. Management has prepared forward-looking statements regarding potential future milestones, such as possible FDA approval of CS Protect-Hydrogel, anticipated timelines for U.S. production, and potential revenue generation. These statements reflect management's current plans and observations, but are inherently subject to numerous risks and uncertainties. | 37 |
| &nbsp;&nbsp;&nbsp;Going forward | 38 |
| **LEGAL PROCEEDINGS** | **38** |
| &nbsp;&nbsp;&nbsp;CS Diagnostics Corp. v. Wilson |  |
| **INDEX TO FINANCIAL STATEMENTS** | **F-1** |

---

3 www.csdcorp.us

**FORWARD-LOOKING STATEMENTS**

This Form 10 contains certain statements that discuss future expectations, contain projections of results of operations or financial condition or state other "forward-looking" information. The words "believe," "expect," "anticipate," "intend," "estimate," "may," "should," "could," "will," "plan," "future," "continue," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters identify forward-looking statements. These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management. Therefore, the actual results could differ materially from these forward-looking statements. This registration statement, including the information contained in the Business, Risk Factors, and MD&A sections, has been prepared under the supervision of the Company's officers and directors, each of whom has reviewed and approved its contents.

**Business**

**Overview**

CS Diagnostics Corp. ("CS Diagnostics," "CSDX," or the "Company") is a medical technology and distribution company focused on developing and commercializing therapeutic and preventive solutions aimed at improving patient care and outcomes. The Company's primary product candidates are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a long-acting surface disinfectant.

The Company's mission is to advance treatment effectiveness while reducing side effects, thereby enhancing patient quality of life. In addition to its own product pipeline, the Company intends to pursue growth through strategic acquisitions, licensing, and joint ventures. Management expects this strategy will focus on pharmaceutical and medical device products that align with the Company's expertise in oncology supportive care, infection control, and distribution of specialty therapeutics. Because these initiatives are in preliminary stages, there can be no assurance that such transactions will be completed or that they will generate revenues.

The Company is a member of the CS Group, an international healthcare group with operations in Europe and the Middle East. The CS Group has historically provided regulatory consulting, product distribution, and business development services in these regions. While the Company benefits from this association, CS Diagnostics is not currently party to material agreements with universities or medical partners referenced in prior disclosure. To the extent such agreements become material in the future, they will be publicly disclosed.

In 2022, the Company determined it required access to the U.S. capital markets to finance its product development and commercialization activities. After evaluating alternatives, CS Diagnostics pursued a reverse merger transaction with a U.S. public shell company. In August 2023, FINRA approved a corporate name change to CS Diagnostics Corp., and the Company now trades on the OTCQB market under the ticker "CSDX."

The Company's business is at an early stage. Neither CS Protect-Hydrogel nor MEDUSA has received marketing authorization in the United States, and there can be no assurance that regulatory approvals will be obtained in a timely manner or at all. Commercial launch of these products, if achieved, will require significant additional financing, regulatory clearances in multiple jurisdictions, and successful execution of manufacturing and distribution plans. Accordingly, any statements regarding potential market share or commercialization timelines should be viewed as forward-looking, subject to substantial risks and uncertainties, and not as assurances of future performance.

4 www.csdcorp.us

With CS PROTECT HYDROGEL ("HYDROGEL"), the CS Diagnostics Group has improved and further developed an existing product. HYDROGEL is a hydrogel-based tissue spacer used in radiation therapy, whose intended but not guaranteed outcome, is to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation to CS Diagnostics Corp. It comes in a sterile, pre-packaged format for easier application, is in liquid form that is administered via injection into the tissue and attempts to accomplish immediate sterility and hygiene. It is the Company's belief that HYDROGEL has the potential but is in no way guaranteeing that the product could gain market share after receiving marketing approval from the Food and Drug Administration ("FDA"). The FDA is the United States federal civilian regulatory agency of the Department of Health and Human Services ("HHS"). Moreover, the FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation.

HYDROGEL's market launch is associated with high costs for FDA approval and marketing. There can be additional delays and unexpected costs in the regulatory approval process. At the end of 2021, the CS Diagnostics Group was faced with the decision to sell the intellectual property of CS PROTECT HYDROGEL or to organize product development, global distribution, cost-intensive product registrations/certifications and global marketing itself. For this reason at the beginning of 2022, CS Diagnostics decided to create an instrument to gain access to the capital market and after careful consideration of various options, the path of a takeover of a US OTC company whose shares are publicly traded and with favorable share structure was chosen. CS Diagnostic Corp. is currently listed on the US OTCQB Markets under the trading symbol "CSDX", (OTCQB- CSDX).

**Corporate History**

The Company was first incorporated under the laws of the State of Nevada on September 25, 1996 under the name "DWC Installations, Inc." Around 2002, the Company changed its name to "The Children's Internet, Inc." On October 20, 2010, it relocated its domicile to Wyoming. Later on February 15, 2015, the Company adopted the name "FlashZero Corp." (the "Flashzero").

On April 4, 2022, after FlashZero's shareholders and CS Diagnostics Pharma GmbH, a German entity, executed a securities purchase agreement, FlashZero ceased its operations. CS Diagnostics Pharma GmbH continued the business under a new name, "CS Diagnostics Corp." and transformed its business model. FINRA approved the name change to 'CS Diagnostics Corp.' on August 3, 2023.

The Company has transformed its business model to that of a medical technology and distribution company. Its activities are focused on the development and distribution of therapeutic and preventive products intended to improve patient care. The Company's stated mission is to pursue technologies that may enhance the effectiveness of treatments and reduce associated side effects, with the objective of improving patient outcomes and quality of life. CS Diagnostics is a member of the "CS Group," an international healthcare group with operations in Europe and Middle East, leveraging global partnerships with universities and medical partners to develop and distribute its products.

 **Parent Company: CS Diagnostics Pharma GmbH** 

Our parent company, CS Diagnostics Pharma GmbH, a German entity ("CS Diagnostics Pharma"), currently holds a majority of our outstanding Common Stock, as well as all of the issued and outstanding Series A Preferred Stock and a majority of the Series B Preferred Stock. Each of these securities carries voting rights and, collectively, provides CS Diagnostics Pharma with majority voting power in the Company. See Description of Capital Stock and Capitalization. The ultimate beneficial owner of CS Diagnostics Pharma is our President and Chief Executive Officer, Mr. Thomas Fahrhoefer.

5 www.csdcorp.us

 **Affiliated Companies** 

We are affiliated with other members of CS Group, including: (i) CS Interpharm General Trading Co. LLC, a Dubai entity, (ii) CS Pharma Handels GmbH, a German entity, (iii) CSI Turkey, a Turkish entity, (iv) CS Diagnostics GmbH, a German entity; and (v) WELL Plus GmbH (dba Deep Oasis), a German entity.

The Company currently has a licensing agreement in place with CS Interpharm General Trading Co. LLC, granting the exclusive rights to distribute one of our products, MEDUSA. See Related Party Transactions for additional information regarding this agreement.

Our corporate structure is illustrated in the diagram below. See also Security Ownership, Description of Capital, and Capitalization for detailed ownership percentages.

![](p982501012ga1_p6chart.jpg)

 **Flagship Product** 

The Company's current core products under development include CS PROTECT Hydrogel and MEDUSA (a long-acting disinfectant), described further below.

6 www.csdcorp.us

**CS Protect-Hydrogel**

This product is a novel tissue spacer gel for use in radiation therapy, designed to separate healthy tissue from malignant tissue during treatment. CS Protect Hydrogel is an injectable "organ spacer" initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. The CS Diagnostics Group was previously the European distributor for the leading first-generation spacer (SpaceOAR®) and has leveraged that experience to develop CS Protect Hydrogel as a second-generation spacer with significant improvements, unlike the incumbent product (now marketed by Boston Scientific Corporation after its $500 million acquisition of Augmenix, Inc. in 2018). CS Diagnostics group is no longer the distributor for SpaceOAR since Boston Scientific's acquisition of Augmentix. Therefore, SpaceOAR is now a competing product of CS Protect Hydrogel since it no longer distributes SpaceOAR.

CS Protect Hydrogel is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. This improves hygiene and ease of use, eliminating a potential contamination step and simplifying application. Moreover, CS Protect Hydrogel's molecular structure and properties enable it to be used in multiple cancer types beyond prostate cancer – e.g. cervical, esophageal, bladder, and breast cancer – whereas the competitor's spacer gel is approved exclusively for prostate use. Management believes these unique advantages (broader applicability, improved safety and convenience) give CS Protect Hydrogel a strong unique selling proposition (USP) in the tissue space market. Management believes that CS Protect-Hydrogel, if successfully approved by the applicable regulatory authorities, may have potential advantages in usability and applicability across multiple cancer types. However, there can be no assurance that regulatory approval will be obtained in a timely manner, or at all, or that the product will achieve market acceptance. The commercial launch will entail significant costs for clinical trials, regulatory approvals, and marketing efforts in each target jurisdiction. On March 2025 the company announced the appointment of a dedicated employee to pursue an FDA approval for its CS Protect Hydrogel. Completion of these trials and studies does not necessarily mean that CS Protect Hydrogel will receive FDA approval.

**<u>Unique Selling Proposition (USP) of CS Protect Hydrogel</u>**

It is the belief of management that CS Protect-Hydrogel is a more advanced hydrogel both from the molecular structure, chemical physical properties and medical applications. The molecular structure of SpaceOAR predominately consists of water and polyethylene glycol (PEG). CS Protect-Hydrogel's molecular structure is… CS Protect-Hydrogel's regulatory classification is…

Compared to the competitor product of Boston Scientific Corporation, CS Protect-Hydrogel has the following practical, hygienic, medical and economic advantages:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Easy application of the CS Protect-Hydrogel since it is a "ready-to-use" product - avoidance of a further work step immediate
application of the CS Protect- Hydrogel after removal from sterile packaging no risk of contamination due to preparation and assembly
of the product exclusion of another hygienic risk area within the treatment room.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. No risk of wrong mixture (especially wrong sequence) and therefore no potential patient's missed appointment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Extended application range; besides prostate cancer also for cervical, esophageal, bladder and breast cancer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Lower personnel costs during treatment due to the elimination of assistance for mixing the hydrogel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. Lower room utilization costs per patient as there is no longer a risk of patients having to be treated again due to incorrect mixtures
(higher number of patients per treatment room) lower cleaning costs due to the ready-to-use principle.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. Fewer lawsuits and/or insurance claims due to incorrectly mixed hydrogels requiring the patient to be treated again.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;g. Lower purchase price as for the competitor product.

7 www.csdcorp.us

**<u>Regulatory Matters and Compliance</u>**

The CS Protect-Hydrogel is a medical device and requires registration or approval by the respective governmental authorities, in particular the Food and Drug Administration (FDA) in the USA or the Federal Institute for Drugs and Medical Devices (BfArM) after CE testing and certification in Germany. Registration or approval is preceded by a testing procedure. The CS Diagnostics Group anticipates a period of 6 to 12 months for approval in the U.S. and 6 to 8 months for the testing procedure and registration of the CS Protect-Hydrogel in Germany.

**MEDUSA (Long-Acting Disinfectant)**

MEDUSA is a proprietary surface disinfectant product developed by CS Diagnostics with an emphasis on long-lasting efficacy and environmental/consumer safety. MEDUSA's formulation provides an extended duration of antimicrobial protection on surfaces – lasting up to 10 days after application, compared to mere hours for many competing disinfectants. The product includes color-changing test strips that allow users to verify the concentration of the active ingredient over time. Because of its long-acting effect, surfaces treated with MEDUSA can be periodically wiped with water between applications without fully removing its protective action. Notably, MEDUSA remains effective even in the presence of organic material (*e.g.* dirt or bodily fluids) on surfaces, an advantage over many existing disinfectants. MEDUSA has already been fully developed and has demonstrated its efficacy in studies (including showing >6-log reduction in viral load for an enveloped virus after 10 days on a treated surface). The Company indicates that obtaining regulatory approvals for MEDUSA as a disinfectant is expected to be straightforward, since the formulation and use-case align with existing regulations for surface disinfectants. CS Diagnostics has reported that it already has several distribution agreements or purchase commitments in place contingent on initial production, and that the primary barrier to commercialization is securing the funds to commence the first large-scale manufacturing lot. MEDUSA's go-to-market strategy will focus on healthcare and institutional markets seeking long-lasting infection control solutions.

**<u>Efficiency of MEDUSA</u>**

To assess the efficacy of MEDUSA, a surface disinfectant, after 10 days on a metal surface. To simulate an area treated with MEDUSA, sterilized test surfaces were sprayed perpendicularly from a distance of 20cm, one pump at a time. As a control, test areas were sprayed with PBS alone. All test areas were then stored under sterile conditions for 10 days at room temperature. After this period, 50μL of the test organisms were dropped onto the test areas and incubated at room temperature for 15 minutes. 1mL of neutralizing solution was then added to stop the action of MEDUSA. A disinfecting effect was determined based on the reduction in the colony forming units (CFU) for bacteria and fungi or the plaque forming units (PFU) for viruses compared to an untreated control sample. A positive effect was determined as a ≥ 5 log reduction for bacteria or ≥ 4 log reduction for viruses and yeasts/fungi.

After 10 days the test solutions of MEDUSA conferred a strong, limited virucidal effect to the surface, demonstrating a greater than 6-log reduction in PFU of Phi-6. A slight reduction in CFU for gram-positive bacteria, gram-negative bacteria and yeasts/fungi was noted. While the necessary log reductions to denote bactericidal/yeasticidal properties were not obtained, it is interesting to note that a mild reduction was observable, nonetheless.

After 10 days on the surface, MEDUSA retained strongly virucidal properties against an enveloped virus, Phi-6.

Medusa is fully Authorized in the European Markets and in the UAE, with manufacturing sites in UAE, Turkey and UK. In June 2025, the company-initiated discussions with an EPA agent to be appointed to pursue full marketing authorization within the US market.

8 www.csdcorp.us

**Leased Offices**

The Company does not directly lease office space. Instead, its affiliate, CS Interpharm General Trading Co. LLC, is the lessee under three ordinary-course office leases that are used for general administrative purposes:

&nbsp;&nbsp;&nbsp;&nbsp;· City of Neuss in Germany (headquarter)

&nbsp;&nbsp;&nbsp;&nbsp;· City of Bruckmühl in Germany

&nbsp;&nbsp;&nbsp;&nbsp;· Dubai, United Arab Emirates

You can find more information about our business on our website at: http://csdcorp.us/

**RISK FACTORS**

*Investing in our company's securities involves a high degree of risk. You should carefully consider and review the risks described below, together with all other information included or referred to in this report before purchasing our shares. There are numerous risks and uncertainties that are not known to us as of the time of this report and we might not consider its significance, which could adversely affect our business, financial condition, or results of operations. In such event, the trading price of our common stock could decline and you may lose all or part of your investment.*

**Risks Related to the Company**

*We expect to incur operating losses and experience negative cash flow and it is uncertain whether we will achieve future profitability.*

We anticipate incurring operating losses until we generate sufficient revenue from our operations. Achieving profitability depends on our ability to ensure our products function as intended, gain market acceptance, and successfully develop and launch additional products and, or services. We cannot guarantee that we will generate sales or reach profitability. As a result, we cannot predict the extent of future losses or how long it may take to achieve profitability, if at all.

*We may need to raise additional funds to finance our capital requirements, which is dilutive to your investment.*

Our cash requirements may vary materially from those now planned depending on numerous factors, including the status of our marketing efforts, our business development activities, the results of future research and development and competition. We may need to raise additional funds to finance our capital requirements through private or public financing before such point for a variety of reasons, including our inability to achieve more substantial revenue operations as we anticipated, and to achieve a profitable level of operations. Such financing could include equity financing, which may be dilutive to members, or debt financing, which would likely restrict our ability to make acquisitions and borrow from other sources. In addition, such securities may contain rights, preferences or privileges senior to those of the rights of our current shareholders. We do not currently have any commitments for additional financing. There can be no assurance that additional funds will be available on terms attractive to us or at all. If adequate funds are not available, we may be required to curtail our pre-production, sales and research and development activities and/or otherwise materially reduce our operations. Any inability to raise adequate funds could have a material adverse effect on our business, results of operation and financial condition.

*We may not be able to attain profitability without additional funding, which may be unavailable.*

9 www.csdcorp.us

We have limited capital resources. Unless we begin to generate sufficient revenues to finance operations as a going concern, the Company may experience liquidity and solvency problems. Such liquidity and solvency problems may force the Company to cease operations if additional financing is not available. No known alternative resources of funds are available in the event we do not generate sufficient funds from operations.

*Our lack of history makes evaluating our business difficult.*

We have a limited operating history and we may not sustain profitability in the future. In order to obtain and sustain profitability, we must:

- compete with larger, more established competitors;

- build, maintain, and enhance our portfolio of pharmaceutical products as well as our overall brand recognition; and

- adapt to meet changes in our markets and competitive developments.

We may not be successful in accomplishing these objectives. Further, our lack of operating history makes it difficult to evaluate our business and prospects. Our prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by companies in their early stages of development, particularly companies in highly competitive industries. The historical information in this report may not be indicative of our future financial condition and future performance.

*Our Articles of Incorporation and Bylaws limit the liability of, and provide indemnification for, our officers and directors.*

Our Articles of Incorporation, generally limits our officers' and directors' personal liability to the Company and its members for breach of fiduciary duty as an officer or director except for breach of the duty of loyalty or acts or omissions not made in good faith or which involve intentional misconduct or a knowing violation of law. Our Articles of Incorporation and Bylaws, provide indemnification for our officers and directors to the fullest extent authorized by the Wyoming Business Corporation Act against all expense, liability, and loss, including attorney's fees, judgments, fines excise taxes or penalties and amounts to be paid in settlement reasonably incurred or suffered by an officer or director in connection with any action, suit or proceeding, whether civil or criminal, administrative or investigative (hereinafter a "Proceeding") to which the officer or director is made a party or is threatened to be made a party, or in which the officer or director is involved by reason of the fact that he is or was an officer or director of the Company, or is or was serving at the request of the Company whether the basis of the Proceeding is an alleged action in an official capacity as an officer or director, or in any other capacity while serving as an officer or director. Thus, the Company may be prevented from recovering damages for certain alleged errors or omissions by the officers and directors for liabilities incurred in connection with their good faith acts for the Company. Such an indemnification payment might deplete the Company's assets. Members who have questions regarding the fiduciary obligations of the officers and directors of the Company should consult with independent legal counsel. It is the position of the Securities and Exchange Commission that exculpation from and indemnification for liabilities arising under the Securities Act of 1933, as amended, and the rules and regulations thereunder is against public policy and therefore unenforceable.

**Risks Related to Business Operations**

*Adverse economic or other conditions in the markets in which we do business could negatively affect our occupancy levels and rental rates and therefore our operating results.*

10 www.csdcorp.us

Our operating results are dependent upon our ability to commercialize our technology. If our technologies fail to generate revenues sufficient to meet our cash requirements, including operating and other expenses, debt service and capital expenditures, our net income, funds from operation (FFO), cash flow, financial condition, ability to make distributions to members and common unit trading price could be adversely affected. The following factors, among others, may adversely affect the operating performance of our properties:

- the national economic climate and the local or regional economic climate in the markets in which we operate, which may be adversely impacted by, among other factors, industry slowdowns, relocation of businesses and changing demographics;

- increased operating costs, including need for research and development, salaries and rent;

- changes in supply of or demand for similar or competing products;

- the impact of changes in regulation;

- earthquakes and other natural disasters, terrorist acts, civil disturbances or acts of war which may result in uninsured or underinsured losses; and

- changes in tax policy.

*Our future revenue and reputation may be affected by litigation or other liability claims.*

We have not procured a general liability insurance policy for our business. To the extent that we suffer a loss of a type which would normally be covered by general liability, we would incur significant expenses in defending any action against us and in paying any claims that result from a settlement or judgment against us. Adverse publicity could result in a loss of consumer confidence in our products.

*As we increase operations, our earnings may be sensitive to fluctuations in market prices and demand for our products and services.*

In addition, after we commence operations, the demand for our pharmaceutical products could decline, whether because of supply or for any other reason, including competing products considered to be superior by end users. A decrease in the selling price received for our products or a decline in demand for our products after we commence operations could have a material adverse effect on our business, results of operations and financial condition

*We have limited marketing capability.*

We have limited marketing capabilities and resources. In order to achieve market penetration, we will have to undertake significant efforts and expenditures to create awareness of, and demand for, our products and services. Our ability to penetrate the market and build our customer base will be substantially dependent on our marketing efforts. Our failure to successfully develop our marketing capabilities, both internally and through third-party alliances, would have a material adverse effect on our business, operating results and financial condition. Further, there can be no assurance that, if developed, such marketing capabilities will lead to sales of our products and services.

11 www.csdcorp.us

*Our investments in product research and development may not yield anticipated returns, which would harm our operating results and reduce the amount of funds available for distributions.*

A key component of our growth strategy is to remain open to exploring new and innovative pharmaceutical or medical technology products through potential acquisitions, licensing arrangements, or joint ventures. These opportunities, if pursued, are intended to complement our current focus on oncology supportive care, infection control, and regulatory distribution services in Europe and the MENA region. However, our ability to identify, evaluate, and successfully integrate such opportunities is uncertain, and any such activities will be subject to significant risks, including:

&nbsp;&nbsp;&nbsp;&nbsp;· our inability to
 obtain financing for acquisitions or partnerships on acceptable terms, or at all;

&nbsp;&nbsp;&nbsp;&nbsp;· the risk that acquired
 or licensed products may not achieve regulatory approval, commercialization, or anticipated
 market acceptance;

&nbsp;&nbsp;&nbsp;&nbsp;· potential delays
 or refusals in obtaining required regulatory approvals for new products; and

&nbsp;&nbsp;&nbsp;&nbsp;· competition from
 more established and better-capitalized companies.

If we are unsuccessful in pursuing or integrating new pharmaceutical opportunities, our growth strategy may not yield the expected benefits and our operating results could be adversely affected.

*We depend heavily on key personnel, and turnover of key senior management could harm our business.*

Our future business and results of operations depend in significant part upon the continued contributions of our Chief Executive Officer. If we lose his services or if he fails to perform in his current position, or if we are not able to attract and retain skilled employees as needed, our business could suffer. A significant turnover in our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend on the skills and abilities of these key employees in managing the product development, marketing and sales aspects of our business, any part of which could be harmed by turnover in the future.

*Because we have a limited history of operations, we may not be able to successfully implement our business plan.*

As a development stage company, we have less than two years of operational history in our industry. Accordingly, our operations are subject to the risks inherent in the establishment of a new business enterprise, including access to capital, successful implementation of our business plan, and limited revenue from operations. We cannot assure you that our intended activities or plan of operation will be successful or result in revenue or profit to us and any failure to implement our business plan may have a material adverse effect on the business of the Company.

*If we fail to effectively manage our growth, our business, brand and reputation, results of operations and financial condition may be adversely affected.*

We may experience rapid growth in operations, which may place significant demands on our management team and our operational and financial infrastructure. As we continue to grow, we must effectively identify, integrate, develop and motivate new employees, and maintain the beneficial aspects of our corporate culture. To attract top talent, we believe we will have to offer attractive compensation packages. The risks of over-hiring or over-compensation and the challenges of integrating a rapidly growing employee base may impact profitability.

Additionally, if we do not effectively manage our growth, the quality of our product offerings could suffer, which could adversely affect our business, brand and reputation, results of operations and financial condition. If operational, research and development and staffing improvements are not implemented successfully, our ability to manage our growth will be impaired and we may have to make significant additional expenditures to address these issues. To effectively manage our growth, we will need to continue to improve our operational, financial and management controls and our reporting systems and procedures.

*We operate in both mature and developing markets, and there is uncertainty as to acceptance of our products and services in these markets.*

We researched the markets for our pharmaceutical products using our own personnel rather than third parties. We have conducted limited test marketing and thus have relatively little information on which to estimate our levels of sales, the amount of revenue our planned operations will generate and our operating and other expenses. There can be no assurance that we will be successful in our efforts to market our products or to develop our markets in the manner we contemplate.

12 www.csdcorp.us

Certain markets are developing and rapidly evolving and are characterized by an increasing number of market entrants who have developed or are developing a wide variety of products and technologies, a number of which offer certain of the features that our products offer. Because of these factors, demand and market acceptance for new products are subject to a high level of uncertainty. Thus, there can be no assurance that our products will become widely accepted. It is also difficult to predict with any assurance the future growth rate, if any, and size of these markets. If a substantial market fails to develop, develops more slowly than expected or becomes saturated with competitors or if our products do not achieve market acceptance, our business, operating results and financial condition will be materially and adversely affected.

*There is a significant amount of competition in our market.*

Our target market is extremely competitive. Competitive factors in the pharmaceutical industry inclusive innovation, cost and other factors. Our primary competitors are expected to include companies with substantially greater financial, technological, marketing, personnel and research and development resources than we currently have. There are direct competitors who have competitive product offerings for the markets we will seek to sell our products in. Further, there can be no assurance that new companies will not enter our markets in the future. Although we believe that our business model will be distinguishable from those of our competitors on the basis of our innovative research and development strategy, there can be no assurance that we will be able to penetrate any of our anticipated competitors'' portions of the market. There can be no assurance that we will be able to compete successfully against currently anticipated or future competitors or that competitive pressures will not have a material adverse effect on our business, operating results and financial condition.

 *We currently distribute SpaceOAR, which could elevate litigation risk.*

SpaceOAR is a first-generation product that is still in wide circulation. HYDROGEL is a second-generation iteration of SpaceOAR, wherein there is a potential of both products to compete against one another. There are several litigation risk factors that could emerge because of the sale of two competing products. First, such an arrangement could lead to antitrust litigation, wherein CS Diagnostics could be accused of price-fixing, bid-rigging, or market allocation. Second, distributing competing products could lead to claims of breaches of contract and warranty if as distributor, CS Diagnostics favors one product over the other. Third, such an arrangement could lead to product liability if CS Diagnostics promoted one product over the other if the latter was found to be defective. Fourth, if CS Diagnostics participates in promoting one product over another, this could subject it to False Claims Act ("FCA"), Medicare, and Medicaid Fraud. Fifth, a competing arrangement could lead to tort claims and defamation if the distributor makes disparaging statements about one product to promote the other. Finally, CS Diagnostics could face claims for indemnification or contribution from one manufacturer if a claim arises related to the other product.

*We are uncertain of our ability to protect our proprietary products.*

In addition to seeking patent protection, we rely on trade secrets, know-how and continuing technological advancement to achieve and thereafter maintain a competitive advantage. Although we have entered into or intend to enter into confidentiality and invention agreements with our employees, consultants, certain potential customers and advisors, no assurance can be given that such agreements will be honored or that we will be able to effectively protect our rights to our unpatented trade secrets and know-how. Moreover, no assurance can be given that others will not independently develop substantially equivalent proprietary information and development techniques or otherwise gain access to our trade secrets and know-how.

13 www.csdcorp.us

*We have not completed our trademark registrations.*

We have not filed for protection for any trademarks in connection with our proposed business and marketing activities. Although we intend to pursue the registration of our marks in the United States and other countries, there can be no assurance that prior registrations and/or uses of one or more of such marks, or a confusingly similar mark, does not exist in one or more of such countries, in which case we might be precluded from registering and/or using such mark in certain countries.

*There are economic and general risks relating to business.*

The success of our activities is subject to risks inherent in business generally, including demand for products and services; general economic conditions; changes in taxes and tax laws; and changes in governmental regulations and policies.

*We may be subject to regulatory inquiries, claims, suits and prosecutions which may impact on our profitability.*

Any failure or perceived failure by us to comply with applicable laws and regulations, in general, may subject us to regulatory inquiries, claims, suits and prosecutions. We can give no assurance that we will prevail in such regulatory inquiries, claims, suits and prosecutions on commercially reasonable terms or at all. Responding to, defending and/or settling regulatory inquiries, claims, suits and prosecutions may be time-consuming and divert management and financial resources or have other adverse effects on our business. A negative outcome in any of these proceedings may result in changes to or discontinuance of some of our services, potential liabilities or additional costs that could have a material adverse effect on our business, results of operations, financial condition and future prospects.

*The laws and regulations concerning data privacy and data security are continually evolving, and our actual or perceived failure to comply with these laws and regulations could harm our business.*

We are and will be subject to federal, state and foreign laws regarding privacy and the protection of the information that we collect regarding our users, which laws are currently in a state of flux and likely to remain so for the foreseeable future. If we fail to follow existing laws and regulations with respect to privacy-related matters or if consumers raise any concerns about our privacy practices, even if unfounded, it could damage our reputation and operating results.

In the area of information security and data protection, many states have passed laws requiring notification to users when there is a security breach for personal data or requiring the adoption of minimum information security standards that are often vaguely defined and difficult to implement. Costs to comply with these laws may increase as a result of changes in interpretation. Furthermore, any failure on our part to comply with these laws may subject us to significant liabilities. Security measures that we put in place to protect our data and the personal information of our employees, customers and partners could be breached due to cyber-attacks initiated by third party hackers, employee error or malfeasance, or otherwise. Because the techniques used to obtain unauthorized access, to disable or degrade service or to sabotage systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. Any breach or unauthorized access could materially interfere with our operations or our ability to offer our services or result in significant legal and financial exposure, damage to our reputation and a loss of confidence in the security of our data, which could have an adverse effect on our business and operating results.

*We may be liable if third parties misappropriate our customers' personal information.*

If third parties are able to penetrate our network security or otherwise misappropriate our customers' personal information or credit card information, or if we give third parties improper access to our customers' personal information or credit card information, we could be subject to liability. This liability could include claims for unauthorized purchases with credit card information, impersonation or other similar fraud claims. This liability could also include claims for other misuses of personal information, including unauthorized marketing purposes.

14 www.csdcorp.us

These claims could result in litigation. Liability for misappropriation of this information could adversely affect our business. In addition, the Federal Trade Commission and state agencies have been investigating various Internet companies regarding their use of personal information. We could incur additional expenses if new regulations regarding the use of personal information are introduced or if government agencies investigate our privacy practices.

We rely on encryption and authentication technology licensed from third parties to provide the security and authentication necessary to effect secure transmission of confidential information such as customer credit card numbers. We cannot assure you that advances in computer capabilities, new discoveries in the field of cryptography or other events or developments will not result in a compromise or breach of the algorithms that we use to protect customer transaction data. If any such compromise of our security were to occur, it could harm our reputation, business, prospects, financial condition and results of operations. A party who is able to circumvent our security measures could misappropriate proprietary information or cause interruptions in our operations. We may be required to expend significant capital and other resources to protect against such security breaches or to alleviate problems caused by such breaches. We cannot assure you that our security measures will prevent security breaches or that failure to prevent such security breaches will not harm our business, prospects, financial condition and results of operations.

**Risks Associated with the Pharmaceutical Industry**

*Regulatory Approval and Compliance Risks*

The pharmaceutical industry is heavily regulated by government authorities, including the U.S. Food and Drug Administration (FDA) and similar agencies in other countries. The development, manufacturing, marketing, and sale of pharmaceutical products are subject to rigorous approval processes and ongoing regulatory compliance. Delays, denials, or the inability to obtain required regulatory approvals could materially and adversely affect the Company's operations and financial performance.

*Research and Development Risks*

The Company's success depends on its ability to develop and commercialize new pharmaceutical products. The process of research and development (R&D) is expensive, time-consuming, and subject to high levels of uncertainty. There is no guarantee that the Company's R&D efforts will result in successful products, or that these products will achieve market acceptance.

*Dependence on Key Products*

The Company may rely heavily on one or more key products for a substantial portion of its revenue. Any disruption in the production, approval, or market acceptance of these products could have a material adverse effect on the Company's financial performance.

*Competition and Market Risks*

The pharmaceutical industry is highly competitive, with many companies, including large multinational corporations, competing for market share. Competitors may develop and market products that are more effective, safer, or less expensive than the Company's products, which could adversely affect its ability to compete successfully.

*Patent Protection and Intellectual Property Risks*

The Company's success depends on its ability to protect its proprietary technology and products through patents and other intellectual property rights. There is no guarantee that the Company will obtain or maintain adequate intellectual property protection. Patent challenges, infringement claims, or the expiration of key patents could adversely affect the Company's competitive position and profitability.

15 www.csdcorp.us

*Manufacturing and Supply Chain Risks*

The pharmaceutical manufacturing process is complex and subject to strict regulatory oversight. The Company may face risks related to supply chain disruptions, manufacturing delays, quality control issues, or reliance on third-party suppliers and contract manufacturers. Any such disruptions could harm the Company's operations and reputation.

*Liability and Litigation Risks*

Pharmaceutical companies are frequently subject to product liability claims and litigation. The Company may face lawsuits related to its products, alleging adverse side effects, improper marketing, or other claims. Such litigation could result in significant legal costs, settlements, or judgments, as well as reputational damage.

*Pricing and Reimbursement Risks*

The pricing of pharmaceutical products is subject to government regulations, healthcare policies, and negotiations with payers, including insurance companies and government programs. Changes in pricing regulations, reimbursement policies, or pricing pressure from payers could negatively impact the Company's revenue and profitability.

*Market Acceptance and Commercialization Risks*

Even if the Company successfully develops and obtains regulatory approval for its products, there is no assurance that these products will achieve market acceptance. Factors such as competition, pricing, marketing strategies, and healthcare provider preferences may impact the commercial success of the Company's products.

*Dependence on Key Personnel*

The Company's success depends on its ability to attract, retain, and motivate highly skilled executives, scientists, and other key personnel. The loss of key employees or the inability to recruit additional qualified personnel could adversely affect the Company's operations and development efforts.

*Risks Related to Changes in Laws and Regulations*

The pharmaceutical industry is subject to frequent changes in laws, regulations, and policies. Changes in healthcare reform, drug approval processes, or other regulatory requirements could increase costs, delay product development, or otherwise negatively impact the Company's business.

*Global Market and Economic Risks*

The Company may operate in or sell products to international markets, exposing it to risks such as currency fluctuations, geopolitical instability, trade restrictions, and economic conditions in foreign countries. These factors could affect the Company's ability to conduct business globally.

*Risks Related to COVID-19 or Other Pandemics*

The pharmaceutical industry may be directly impacted by public health emergencies, including pandemics such as COVID-19. Such events could disrupt the Company's supply chain, R&D efforts, regulatory approval processes, or market demand for its products.

16 www.csdcorp.us

**Risks Related to being a Publicly Traded Company**

*Market Volatility*

The Company's common stock is publicly traded, and the market price of the stock may experience significant volatility due to various factors, including financial results, changes in the Company's business or industry, general market conditions, and economic trends. Such volatility may impact on the valuation of the Company and, indirectly, the value of the Shares.

*Potential Dilution* 

As a publicly traded company, the Company may issue additional shares of common or preferred stock in the future, which could dilute the interests of existing shareholders, including investors in the offered securities. Such dilution may result from financing activities, employee compensation plans, or strategic transactions.

*Dependence on Market Perception* 

The performance and valuation of the Company's publicly traded common stock may depend significantly on market perception and investor sentiment. Negative news, adverse developments, or unfavorable market conditions could harm the Company's reputation and adversely impact its financial condition and operations.

*Compliance with Public Company Reporting Obligations* 

As a publicly traded company, the Company is subject to periodic reporting and other disclosure requirements under applicable securities laws. Compliance with these obligations involves significant costs, and any failure to timely or accurately meet these requirements could result in regulatory penalties, reputational harm, and adverse impacts on the Company's financial performance.

*Insider Ownership and Control*

Our President and Chief Executive Officer, Mr. Thomas Fahrhoefer, as the ultimate beneficial owner of both CS Diagnostics Pharma GmbH and CS Interpharm General Trading Co. LLC, holds a majority of our outstanding voting securities, including 66.90% of the outstanding common stock, 100% of the outstanding Series A Preferred Stock, and 68.31% of the outstanding Series B Preferred Stock. As a result, these insiders exercise significant control over all matters requiring shareholder approval, including the election of directors, approval of mergers or other business combinations, and other significant corporate actions. This concentration of ownership may:

&nbsp;&nbsp;&nbsp;&nbsp;· reduce the ability
 of minority shareholders to influence or approve corporate decisions;

&nbsp;&nbsp;&nbsp;&nbsp;· delay, defer, or
 prevent a change in control of the Company, even when such a transaction may be favorable
 to other shareholders;

&nbsp;&nbsp;&nbsp;&nbsp;· discourage potential
 acquirers from making a tender offer or pursuing other transactions; and

&nbsp;&nbsp;&nbsp;&nbsp;· permit our controlling
 shareholder to determine his own compensation and perquisites, which could reduce funds available
 for net income or reinvestment in the business.

This concentration of ownership and voting power could conflict with the interests of our minority shareholders and may adversely affect the value of their investment.

*Risks of Delisting or Trading Suspension* 

The Company's common stock is listed on OTC Markets. If the Company fails to meet applicable listing or trading requirements, its stock could be delisted or suspended from trading, which could significantly impair its liquidity and value, as well as the Company's ability to raise capital.

*Litigation and Regulatory Risks* 

Publicly traded companies often face heightened risks of shareholder litigation, regulatory scrutiny, and enforcement actions. Such risks could result in significant legal costs, settlements, or damages and may adversely impact the Company's financial condition.

17 www.csdcorp.us

*Impact of Securities Laws on Resale of Shares* 

The Company's status as a publicly traded company may subject investors to certain legal and regulatory restrictions on the resale of the offered securities, particularly if the resale involves significant ownership stakes or affiliates of the Company.

*Disclosure of Material Non-Public Information* 

As a publicly traded company, the Company must carefully manage its disclosure obligations. Purchasers of the offered securities should be aware that they may, at times, have access to material non-public information that could restrict their ability to trade in the Company's publicly traded securities under applicable insider trading laws.

*We may, in the future, issue additional Shares which would reduce investors' percentage of ownership and may dilute our common membership unit value.*

Our Articles of Incorporation authorize the issuance of 4,000,000 shares of the Series C Preferred Stock. The issuance of Preferred Stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the units held by our investors and might have an adverse effect on any trading market for our common units.

*We are subject to compliance with securities law, which exposes us to potential liabilities, including potential rescission rights.*

We may offer to sell our securities to investors pursuant to certain exemptions from the registration requirements of the Securities Act of 1933, as well as those of various state securities laws. The basis for relying on such exemptions is factual; that is, the applicability of such exemptions depends upon our conduct and that of those persons contacting prospective investors and making the offering. We may not seek any legal opinion to the effect that any such offering would be exempt from registration under any federal or state law. Instead, we may elect to relay upon the operative facts as the basis for such exemption, including information provided by investor themselves. If any such offering did not qualify for such exemption, an investor would have the right to rescind its purchase of the securities if it so desired. It is possible that if an investor should seek rescission, such investor would succeed. A similar situation prevails under state law in those states where the securities may be offered without registration in reliance on the partial preemption from the registration or qualification provisions of such state statutes under the National Securities Markets Improvement Act of 1996. If investors were successful in seeking rescission, we would face severe financial demands that could adversely affect our business and operations. Additionally, if we did not in fact qualify for the exemptions upon which it has relied, we may become subject to significant fines and penalties imposed by the SEC and state securities agencies.

*There is no current established trading market for our Shares and if a trading market does not develop, purchasers of our securities may have difficulty selling their Shares.*

There is currently no established public trading market for our Shares and an active trading market in our Shares may not develop or, if developed, may not be sustained. No market makers have committed to becoming market makers for our Shares and none may do so in the future.

*Because we do not intend to pay any cash dividends on our Shares our members will not be able to receive a return on their Shares unless they sell them.*

We intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our Shares in the foreseeable future. Unless we pay dividends, our members will not be able to receive a return on their Shares unless they sell them. There is no assurance that members will be able to sell Shares when desired.

18 www.csdcorp.us

 *Our ability to meet the standards to be listed on a national exchange has been materially impacted by a recent shareholder action and related litigation.*

In early 2025, a minority shareholder disposed of a large volume of CSDX shares, contributing to a significant decline in our stock price from approximately $3.00 per share in late 2024 to sub-penny levels. This activity, and the resulting loss of market confidence, has impaired our relationships with potential investors and service providers, and has forced us to initiate litigation against the shareholder. While the outcome of this litigation is uncertain, the immediate impact has been to delay and potentially jeopardize our plans to meet the quantitative and qualitative requirements for listing on a national securities exchange. There can be no assurance that we will be able to restore investor confidence, achieve the necessary share price levels, or otherwise satisfy the listing criteria in the near future.

*Following on next page*

19 www.csdcorp.us

**SECURITY OWNERSHIP**

**Beneficial Owners and Management**

The following table sets forth information with respect to the beneficial information of our Common Stock and Preferred Stock as of March 31, 2025:

&nbsp;&nbsp;&nbsp;&nbsp;· Each person who
 we know to beneficially owns more than 5% of our outstanding voting securities (*i.e.* Common
 Stock, Series A Preferred Stock, and Series B Preferred Stock),

&nbsp;&nbsp;&nbsp;&nbsp;· Each of our director
 and named executive officer, and

&nbsp;&nbsp;&nbsp;&nbsp;· All directors and
 executive officers as a group.

Beneficial ownership is determined in accordance with Rule 13d-3 under the Exchange Act and includes voting and/or investment power with respect to securities. Percentages are based on the following issued and outstanding stock of the Company as of March 31, 2025, see below. See also Risk Factors—Insider Ownership and Control, Description of Capital Stock, and Capitalization.

&nbsp;&nbsp;&nbsp;&nbsp;· Common Stock: 137,340,200
 shares

&nbsp;&nbsp;&nbsp;&nbsp;· Series A
 Preferred: 10 shares

&nbsp;&nbsp;&nbsp;&nbsp;· Series B
 Preferred: 19,992,575 shares

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Name of Beneficial Owner/ Officer/ <br> Director or Control Person<sup>1</sup>** | **Affiliation with<br> Company** <br> **(Officer/Director/<br> Owner of more<br> than 5%)**  | **Number of <br> shares <br> owned** | **Share <br> type/class** | **Ownership<br> Percentage of** <br> **Class<br> Outstanding**  |
| Thomas Fahrhoefer | President & CEO | 91881896 | Common | 66.90% |
| &nbsp;&nbsp;&nbsp;&nbsp; CS Diagnostics Pharma GmbH<sup>2</sup> | >5% | 74855800 | Common | 54.50% |
| &nbsp;&nbsp;&nbsp;&nbsp; CS Interpharm General Trading Co. LLC<sup>3</sup> | > 5% | 17026096 | Common | 12.40% |
| Thomas J Migotsch | Chief Operational Officer, Board of Director | 480000 | Common | 0.35% |
| Thomas Fahrhoefer | President & CEO | 10 | Preferred A | 100.00% |
| &nbsp;&nbsp;&nbsp;&nbsp; CS Diagnostics Pharma GmbH<sup>3</sup> | >5% | 10 | Preferred A | 100.00% |
| Thomas Fahrhoefer | President & CEO | 13655206 | Preferred B | 68.31% |
| &nbsp;&nbsp;&nbsp;&nbsp; CS Diagnostics Pharma GmbH<sup>3</sup> | >5% | 7924180 | Preferred B | 39.64% |
| &nbsp;&nbsp;&nbsp;&nbsp; CS Interpharm General Trading Co. LLC<sup>4</sup> | > 5% | 5731026 | Preferred B | 28.67% |
| Association Continental de Reassurance NV<sup>4</sup> | >5% | 1499625 | Preferred B | 7.50% |
| Thomas Graus | Board of Director | 1273737 | Preferred B | 6.40% |
| Antonio Santoli | >5% | 1273737 | Preferred B | 6.40% |

---

 

<sup>1</sup> Unless otherwise indicated, the business address of each beneficial owner is c/o CS Diagnostics Corp.

<sup>2</sup> Shares held by CS Diagnostics Pharma GmbH are beneficially owned and controlled by Mr. Thomas Fahrhoefer, who is the Company's President and Chief Executive Officer.

<sup>3</sup> Shares held by CS Interpharm General Trading Co. LLC are beneficially owned and controlled by Mr. Thomas Fahrhoefer, who is the Company's President and Chief Executive Officer.

<sup>4</sup> Shares held by Association Continental de Reassurance NV are beneficially owned and controlled by Adriaan Vangelabbeek Antwerpen.

 

20 www.csdcorp.us

 

Note: As of March 31, 2025, our President and Chief Executive Officer, Mr. Thomas Fahrhoefer, beneficially owns 66.90% of our outstanding common stock, 100% of our outstanding Series A Preferred Stock, and approximately 68.31% of our outstanding Series B Preferred Stock. Because the Series A Preferred Stock carries super-voting rights and the Series B Preferred Stock votes on a one-for-one basis with our common stock, Mr. Fahrhoefer effectively controls all matters submitted to a vote of our shareholders. This concentration of ownership allows him to exercise significant influence over the election of directors, approval of mergers and acquisitions, amendments to our charter documents, and other significant corporate matters.

As a result, Mr. Fahrhoefer's control may limit the ability of minority shareholders to influence corporate decisions, and may delay, defer, or prevent a change in control of the Company. See Risk Factors—Insider Ownership and Control, Description of Capital Stock, and Capitalization.

**DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE<br> GOVERNANCE**

**Directors and Officers**

The following table sets forth the names, positions and ages of our directors and/or executive officers. Our directors were elected by the majority written consent of our stockholders in lieu of a shareholder's disclosure. Our directors are elected at each annual meeting and serve for one year and until their successors are elected and qualified. Officers are elected by our board of directors and their office terms are at the discretion of our board.

---

| | |
|:---|:---|
| Name | Position |
| Thomas Fahrhoefer | President, Chief Executive Officer, & Chairman of the Board of Directors |
| Mohammad EsSayed | Vice President, Chief Financial Officer, & Director |
| Sabrina Kummer Godehardt | Business Development, & Director |
| Janel Luzana | Corporate Secretary |
| Mahmoud A. Al-Sayyed | Independent Director |
| Dr. Ralf Herwig | Independent Director |

---

**Thomas Fahrhoefer**

Mr. Fahrhoefer, born in 1970, is the founder of the CS Diagnostics Group and an expert in pharmaceutical distribution and healthcare business development. After studies in medicine and pharmacy, he built a career in pharmaceutical sales and management, including roles at Pfizer Germany (2001–2003) and Sanochemia AG (in the diagnostics business unit). In 2009, Mr. Fahrhoefer founded CS Diagnostics in Germany, growing it into the current CS Diagnostics Group comprising CS Diagnostics Pharma GmbH, CS Interpharm LLC, and CS Diagnostics Corp.. Under his leadership, the Company is pursuing innovative solutions like the CS Protect Hydrogel. Mr. Fahrhoefer has been the President and a Director of the Company since the April 2022 change-in-control, and he also serves as the Chairman of the Board.

21 www.csdcorp.us

**Mohammad EsSayed**

Born in 1978, has over 22 years of professional experience in finance, banking, and executive management. He holds multiple finance degrees and certifications, including an MBA in International Corporate Banking and the CFA (Chartered Financial Analyst) designation. Prior to joining CS Diagnostics, Mr. EsSayed served as CFO and Managing Director for other companies, and he has a strong background in financial planning, corporate finance, and governance. CS Diagnostics benefits from his extensive financial management experience. He was appointed as CFO and Vice President of the Company in 2022. In this capacity, Mr. EsSayed manages the Company's financial strategy, accounting and reporting, and investor relations functions.

**Sabrina Kummer Godehardt**

Sabrina Godehardt, born on March 16, 1980 in Bad Langensalza, Germany is a certified office communication clerk with over 15 years of experience in medical administration and practice management. She worked as practice manager in a radiology and nuclear medicine clinic from 2015 to 2024, with additional responsibility for IT systems. Since June 2024, she serves as Head of Sales Coordination at CS Diagnostics Pharma GmbH. She holds IHK certifications in practice and marketing management and is proficient in MS Office, Lexware, PACS/RIS systems, and various administrative tools.

**Janel Luzana**

Ms. Luzana serves as the Company's Corporate Secretary, responsible for corporate records, compliance with corporate governance requirements, and assisting the executive team on legal/administrative matters. She joined the Board as part of the 2022 reorganization. Ms. Luzana's professional biography is not elaborated in the available disclosure, but she is identified as the Corporate Secretary in official filings.

**Mahmoud A. Al-Sayyed**

Mahmoud A. Al-Sayyed is a senior executive nearly three decades of experience in investment advisory, corporate strategy, and governance. His background includes expertise in IPOs, mergers and acquisitions, business valuation, and financial modeling. He has held various leadership and board positions, bringing a wealth of management and oversight experience. Mr. Al-Sayyed's career highlights include developing corporate strategies, executing performance management programs, and serving on supervisory boards and board committees in an advisory capacity. He joined CS Diagnostics Corp. as an independent Board member to provide guidance on corporate finance, strategy, and compliance.

**Dr. Ralf Herwig**

Dr. Ralf Herwig is a board-certified physician since 1995 with a doctorate in medicine (magna cum laude) and habilitation in urology. He holds professorial titles and serves as President of both the Austrian Andrological Society and the International Autism Association (2025). His expertise spans urology, andrology, minimally invasive surgery, molecular biology, and sexual medicine, supported by extensive scientific training and over a dozen memberships in international medical societies. He is Editor-in-Chief of multiple scientific journals and has received several prestigious awards for his research.

**Executive Compensation**

On July 18<sup>th</sup> 2025, a shareholder resolution has been issued for changes in CSDX board of directors as follows:

Mr. Thomas Migotsch as well as the previous independent director Dr. Lauren Kate Ugur were replaced by Ms. Sabrina K. Godehardt as Director of Business Development, and Dr. Ralf Herwig as independent director.

22 www.csdcorp.us

On August 9<sup>th</sup> 2024, a shareholder resolution has been issued for changes in CSDX board of directors as follows: Mr. Thomas Migotsch and Mr. Thomas Graus as well as the previous independent directors Mrs. Csilla Kanderka and Mrs. Delia-Alexandra Kreutner were replaced by Mr. Mohammad EsSayed as VP, Director and CFO, Mr. Thomas Migotsch remains a director and assigned as COO, Dr. Lauren Ugur and Mr. Mahmoud Ahmad Hashim AL-Sayed take on their role as independent directors, and Ms. Janel Luzana as an Officer and Company Secretary.

It was agreed that Mr. Thomas Graus will receive compensation of $72,000 for this year, 2025. The rest of the officers & Directors receive compensation through their ownership and focus on building the Company's value. As the Company grows and potentially uplists in the future, it may adopt market-based executive compensation and establish employment contracts. For now, the management team aligns its interests closely with shareholders, given their significant stock holdings.

Officer:

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and <br> principal <br> position** | **Fiscal <br> Year** | **Salary <br> ($)** | **Bonus <br> ($)** | **Stock <br> Awards <br> ($)** | **Option <br> Awards <br> ($)** | **Non-<br> equity <br> incentive <br> plan <br> compensation** | **Non-<br> qualified <br> deferred <br> compensation <br> earnings** | **All other <br> compensation** | **Total <br> ($)** |
| Thomas Fahrhoefer |  |  |  |  |  |  |  |  |  |
| Thomas Migotsch |  |  |  |  |  |  |  |  |  |

---

Director:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and <br> principal <br> position** | **Fees earned <br> or paid in <br> cash($)** | **Stock <br> Awards <br> ($)** | **Option <br> awards <br> ($)** | **Non-equity <br> incentive plan <br> compensation**  | **Non-qualified <br> deferred <br> compensation <br> earnings** | **All other <br> compensation** | **Total <br> ($)** |
| Thomas Fahrhoefer |  |  |  |  |  |  |  |
| Thomas Migotsch |  |  |  |  |  |  |  |

---

**Limitation of Liability and Indemnification**

The Wyoming Business Corporation Act (the "Act"), under which the Company is organized, permits the inclusion in the Articles of Incorporation of a provision limiting or eliminating the potential monetary liability of directors to a corporation or its stockholders by reason of their conduct as directors. The provision would not permit any limitation on or the elimination of liability of a director for disloyalty to his corporation or its stockholders, failing to act in good faith, engaging in intentional misconduct or a knowing violation of the law, obtaining an improper personal benefit or paying a dividend or approving a stock repurchase that was illegal under the Act. Accordingly, the provisions limiting or eliminating the potential monetary liability of directors permitted by the Act apply only to the "duty of care" of directors, i.e., to unintentional errors in their deliberations or judgments and not to any form of "bad faith" conduct.

23 www.csdcorp.us

The Articles of Incorporation of the Company contain a provision which eliminates the personal monetary liability of directors to the extent allowed under Wyoming law. Accordingly, a stockholder is able to prosecute an action against a director for monetary damages only if he can show a breach of the duty of loyalty, a failure to act in good faith, intentional misconduct, a knowing violation of law, an improper personal benefit or an illegal dividend or stock repurchase, as referred to in the amendment, and not "negligence" or "gross negligence" in satisfying his duty of care. The Act applies only to claims against a director arising out of his role as a director and not, if he is also an officer, his role as an officer or in any other capacity or to his responsibilities under any other law, such as the federal securities laws.

In addition, the Company's Articles of Incorporation provides that the Company will indemnify our directors, officers, employees and other agents to the fullest extent permitted by Wyoming law. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

No pending litigation or proceeding involving a director, officer, employee or other agent of the Company as to which indemnification is being sought exists, and the Company is not aware of any pending or threatened material litigation that may result in claims for indemnification by any director, officer, employee or other agent.

**Stock and Stock Option Issuances in 2023 and 2024**

The following table details all stock and stock option issuances made to Company officers and directors during fiscal years 2023 and 2024:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **<u>Date</u>** | **<u>Securities</u>** | **<u>Class of <br> Securities</u>** | **<u>Amount <br> Per Share</u>** | **<u>Issued To</u>** | **<u>Purpose</u>** | **<u>Exemption</u>** |
| 08/01/23 | (134974014) | Common | $0.0001 | All Shareholders | Reverse Split: 1 for 100,000 and forward split 1 to 200 | 4(a)(2) |
| 09/27/23 | 65000000 | Common | $4.54 | CS Diagnostics Pharma GmbH (1) | Asset Purchase Agreement | 4(a)(2) |
| 09/27/23 | 20000000 | Common | $4.54 | CS Interpharm LLC (2) | Asset Purchase Agreement | 4(a)(2) |

---

<u>Notes:</u>

1. The beneficial owner is the Company's Chief Executive Officer, President and Director Thomas Fahrhoefer

2. The beneficial owner is the Company's Chief Executive Officer, President and Director Thomas Fahrhoefer

24 www.csdcorp.us

**Related Party Transactions**

During fiscal year 2023 the Company entered into two asset purchase agreements with entities controlled by our Chief Executive Officer Thomas Fahrhoefer relating to the Company's acquisition of certain intellectual property controlled by Mr. Fahrhoefer. See Recent Issuances of Securities.

*Following on next page*

25 www.csdcorp.us

**DESCRIPTION OF CAPITAL STOCK**

**Common Stock**

The Company is authorized to issue up to 250,000,000 Shares of Common Stock, $0.00001 par value per share, of which 137,340,200 are issued and outstanding. Holders of our common stock are entitled to one vote for each share in the election of directors and on all matters submitted to a vote of stockholders. There is no cumulative voting in the election of directors.

The holders of the common stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore.

Upon the liquidation, dissolution or winding up of the Company, the remaining assets of the Company available for distribution to stockholders will be distributed among the holders of Common Stock, pro rata based on the number of Shares of common stock held by each.

Holders of common stock generally have no preemptive, subscription, redemption or conversion rights. The outstanding Notes of common stock are, when issued, fully paid and nonassessable.

As of June 30, 2025, we have 317 shareholders of record, and our outstanding common shares is 137,340,200.

**Preferred Stock**

The Company is authorized to issue up to 25,000,000 shares of Preferred Stock, par value $0.0001 per share, of which 19,992,585 shares are issued and outstanding. The Company has created three (3) classes of preferred stock with distinct rights and privileges.

**Series A Preferred Stock**

The Company is authorized to issue up to 1,000,000 shares of Series A Preferred Stock, of which 10 shares are issued and outstanding. The holder of the Series A Preferred Stock are entitled to vote pari passu with holders of the Company's common stock on the following basis: four times the sum of (a) the total number of shares of common stock which are issued and outstanding together with; (b) the total number of shares of any other series of preferred stock which are issued and outstanding.

The holders of the Series A Preferred Stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore.

The holder of the Series A Preferred Stock holds a dividend preference over the Series B Preferred Stock and common stock of the Company.

Upon liquidation, the holders of the Series A Preferred Stock are entitled to receive an amount equal to the sum of (a) the original issue price of the Series A Preferred Stock multiplied by; (b) the number of shares of Series A Preferred Stock owned by such holder upon liquidation, as adjusted for any for any recapitalizations. This right is senior to any other class of securities of the Company.

**Series B Preferred Stock**

The Company is authorized to issue up to 20,000,000 shares of Series B Preferred Stock, of which 19,992,575 shares are issued and outstanding. Holders of the Series B Preferred Stock are entitled to convert each share of stock into 20,000 shares of the Company's common stock, with the limitation of no greater than 9.9% of the total issued and outstanding common stock of the Company.

26 www.csdcorp.us

The holder of the Series B Preferred Stock are entitled to vote pari passu with holders of the Company's common stock on a one-to-one basis.

The holders of the Series B Preferred Stock are entitled to receive dividends, when and as declared, from time to time, by our board of directors, in its discretion, out of any assets of the Company legally available therefore. The holder of the Series B Preferred Stock holds a hold a dividend preference junior in right to that of the Series A Preferred Stock and Series C Preferred Stock but senior in right to the common stock of the Company.

Upon an event of liquidation, the holders of the Series B Preferred Stock are entitled to receive, to the extent available, an amount equal to $1.00 per share, as adjusted for any stock dividends, splits, combinations and capitalization, plus all declared but unpaid dividends.

**Series C Preferred Stock**

The Company is authorized to issue up to 4,000,000 shares of Series C Preferred Stock, of which zero (0) shares are issued and outstanding. The Series C Preferred Stock does not carry any voting rights.

Holders of the Series C Preferred stock are entitled to receive an annual dividend in the amount of 6.5% of the stated value of $1,000 per share, payable in arrears. All unpaid dividends shall accrue. The Series C Preferred Stock carries a dividend preference over all other classes of securities of the Company.

Upon an event of liquidation, the holders of the Series C Preferred Stock are entitled to receive, to the extent available, an amount equal to the stated value together with any accrued but unpaid dividends. The Series C Preferred stock carries a liquidation preference over the common stock of the Company.

**Recent Issuances of Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Date of Transaction | Transaction Type (*e.g.* new issuance, cancellation, shares returned to treasury) | Number of Shares Issued (or cancelled) | Class of Securities | Value of Shares Issued ($/per share) at Issuance | Were the shares issued at a discount to market price at the time of issuance (Yes/No) | Reason for share issuance (*e.g.* for cash or debt conversion) - OR- Nature of Services Provided | Restricted or Unrestricted as of this filing. | Exemption or Registration Type |
| 05-09-2022 | Issuance | 10011000 | Preferred Series B | 1000 | No Patientrac Limited<sup>1</sup> | Pursuant to the Securities<br> Purchase<br> Agreement for services<br> rendered, *e.g.*<br> acquisition costs,<br> payments and organization reinstatements | Restricted | 4(a)(2) |

---

27 www.csdcorp.us

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| 08-01-2023 | Corporate Action Reverse split 1 to 100,000 and Forward Split 1 to 200 | -134497014 | Common | 0.00001 | No | Same | Restricted and Unrestricted | 4(a)(2) |
| 09-27-2023 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Issuance<br>| 65000000 | Common | $4.54 | No CS Diagnostics Pharma GmbH<sup>2</sup> | Asset Purchase Agreement | Restricted | 4(a)(2) |
| 09-27-2023 | Issuance<br>| 20000000 | Common | $4.54 | No CS Interpharm LLC<sup>2</sup> | Asset Purchase Agreement | Restricted | 4(a)(2) |

---

<u>Note</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. PatientTrac Limited is a United Kingdom company whose beneficial owner is H Wayne Hayes, Jr. of Bogota, Colombia and held these shares
in trust. PatientTrac, pursuant to the Securities Purchase Agreement dated 30 March 2022 with CS Diagnostics Pharma GmbH, has agreed and
on July 9, 2022 transferred the 10,011,000 to CS Diagnostics Pharma GmbH designees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The beneficial owner of both CS Diagnostics Pharma GmbH and CS Interpharm LLC is Thomas Fahrhoefer, Dubai, UAE.

*Following on next page*

28 www.csdcorp.us

**CAPITALIZATION**

CS DIAGNOSTICS CORP. (CSDX) <br> BALANCE SHEET <br> FOR THE PERIOD ENDED MARCH 31, 2025

---

| | | |
|:---|:---|:---|
|  | Mar. 31, 2025 | Dec. 31, 2024 |
|  | *Un-Audited* | *Audited* |
| *Assets* |  |  |
| **Current Assets** |  |  |
| Cash | 51386 | 501 |
| Other Receivables | 54726 |  |
| **Total Current Assets** | $**106112** | $**501** |
| Intangible Assets | 499400000 | 499400000 |
| **Total Assets** | $**499506112** | $**499400501** |
| *Liabilities and Stockholders' Deficit* |  |  |
| **Current Liabilities** |  |  |
| Account Payables | 2931 | 1428 |
| Non-current liabilities | 0 | 0 |
| **Total Liabilities** | **74931** | **1428** |
| **Shareholder's Deficit** |  |  |
| Common stock, $0.00001 par value; 250,000,000 shares <br> authorized 137,340,200 shares issued and outstanding as of March 31, 2025 | 1373 | 1373 |
| Preferred stock Series A, $0.00001 par value;5,000 shares authorized, 10 <br> shares issued and outstanding as of March 31, 2025 |  |  |
| Preferred stock Series B, $0.00001 par value; 20,000,000 shares authorized, <br> 19,992,575 shares issued and outstanding as of March 31, 2025 | 2000 | 2000 |
| Preferred stock Series C, $0.00001 par value; 4,000,000 shares authorized, 0 <br> shares issued and outstanding as of March 31, 2025 | 40 |  |
| Additional paid-in capital | 504163629 | 504163629 |
| Accumulated deficit | (4735861) | (4767928) |
| **Total Stockholders' Deficit** | $**499431181** | $**499399073** |
| **Total Liabilities and Stockholders' Deficit** | $**499506112** | $**499400501** |

---

NOTE: *This is an unaudited financial statement, that can be subject to minor changes upon Auditor review*

29 www.csdcorp.us

**Management's Discussion and Analysis of Financial Condition and Results of Operation (MD&A)**

**Overview and Business Summary**

CS Diagnostics Corp. ("CSDX" or "the Company") is a medical technology company focused on improving therapy outcomes in cancer treatment and reducing side effects for patients. The Company provides medical industry partners with access to international markets and regulatory approval services in Europe and the Middle East/North Africa (MENA) region, while also developing its own innovative products. In August 2023, CSDX underwent a corporate reorganization – changing its name from FlashZero Corp. to CS Diagnostics Corp. – and repositioned itself in the healthcare sector. A pivotal event was the acquisition of the CS Protect-Hydrogel technology in September 2023, when CSDX purchased 100% of the rights, intellectual property, and patents for this product from its parent group. CS Protect-Hydrogel is a hydrogel-based tissue spacer used in radiation therapy to increase the distance between malignant tumors and healthy tissue, thereby protecting healthy tissue from high-dose radiation damage. This spacer is injected in liquid form into the space between cancerous and healthy tissues (e.g. between the prostate and rectum in prostate cancer), and it biodegrades after about six months. Importantly, CS Protect-Hydrogel is a sterile, "ready-to-use" product that can be applied directly without on-site preparation, and it is intended for use not only in prostate cancer radiotherapy but also in other cancer types such as cervical, esophageal, bladder, and breast cancers.

As of the end of 2024 and through the first quarter of 2025, the Company's primary focus has been advancing the CS Protect-Hydrogel toward commercialization and regulatory approval, while managing its financial position following its reorganization. The Company's common stock is quoted on the OTCQB market under the ticker "CSDX." In addition to the hydrogel product, CSDX has begun to diversify its portfolio. In January 2025, the Company launched MEDUSA, a next-generation disinfectant product, in limited U.S. marketa. MEDUSA is an advanced long-acting surface disinfectant that has received regulatory clearance in the EU and UAE and is currently pending regulatory approval in the United States. MEDUSA's commercialization is at an early stage, and its future market acceptance, sales levels, and regulatory outcomes remain uncertain.

Management has noted third-party industry reports estimating that the global disinfectant market exceeds USD 8 billion annually, including a 2024 estimate of approximately USD 8.4 billion from Persistence Market Research and a 2023 estimate of USD 8.6 billion from Allied Market Research. These figures are based on current market conditions and are highly dependent on data provider methodologies and definitions of market scope. There can be no assurance that the Company will capture any meaningful share of this market or achieve significant commercial success. We cannot give assurance on our ability to penetrate this market, the extent of any market share it may achieve, or the timing of such results. The inclusion of MEDUSA in the Company's product lineup reflects management's strategy to expand its operations by leveraging its experience with regulatory approvals and product distribution. CS Protect-Hydrogel remains the Company's lead product candidate and the central focus of its development activities. Management, under the supervision of the Company's executive officers and directors, has prepared this discussion and analysis to reflect the Company's current operations, strategy, and expectations.

**Results of Operations**

**Fiscal Year 2024 Compared to 2023**

For the fiscal year ended December 31, 2024, the Company generated modest revenues of $110,911, compared to $126,038 in the prior year 2023. This slight decline in revenue year-over-year reflects the Company's early-stage operations and a continued focus on product development and regulatory preparation. We note that these revenues likely stem from CSDX's legacy service business (assisting with medical product distribution/approvals) or initial product sales, as full commercial sales of CS Protect-Hydrogel had not commenced by 2024. Despite the small decrease in top-line, the Company's bottom-line improved year-over-year. CSDX reported a net profit of $761 for 2024, a turnaround from a net loss of $21,997 in 2023. This swing to roughly break-even results was achieved primarily through expense management.

30 www.csdcorp.us

Operating expenses in 2024 totaled $110,150, down 25% from $148,035 in 2023. Notably, general and administrative (G&A) expenses were sharply lower in 2024 (only $395, versus $94,009 in 2023), indicating significant cost-cutting or the absence of prior-year one-time costs. By contrast, professional fees (which can include legal, consulting, and accounting costs) increased to $109,755 in 2024 from $54,026 in 2023. The higher professional fees in 2024 are attributable to corporate activities such as auditing, regulatory compliance, and the transactions surrounding the hydrogel asset acquisition and public listing process. These professional costs were largely offset by the drastic reduction in G&A overhead, resulting in near break-even operating income of $761 for 2024 (versus a $21,997 operating loss in 2023). The improvement reflects management's efforts to streamline operations and focus expenditures on essential corporate and development activities. Basic and diluted earnings per share were $0.00 for both years, given the negligible net income and the Company's expanded share count after the 2023 equity issuance for the hydrogel acquisition. Weighted average shares outstanding increased from about 110.8 million in 2023 to 137.3 million in 2024, reflecting new shares issued as part of the asset purchase and any other equity issuances during 2024.

**Quarter Ended March 31, 2025 Compared to March 31, 2024**

For the first quarter of 2025, CSDX reported revenue of $70,420, representing growth compared to approximately $53,258 in the first quarter of 2024. This year-over-year quarterly increase (~32%) suggests early traction in the Company's business activities, potentially from higher service revenue or initial sales of its products (including possibly the first contributions from MEDUSA's rollout or increased demand for the Company's regulatory consulting services). First quarter revenues outpaced operating expenses, leading to positive operating income. Operating expenses for Q1 2025 were $38,353, higher than the unusually low $8,564 reported in Q1 2024. The increase in expenses is largely due to a normalization of G&A costs and continued professional services as the Company scales its operations. In Q1 2024, CSDX's G&A expense was virtually nil (only $140), reflecting minimal staffed operations at that time, whereas in Q1 2025 G&A was $21,834 as the Company began incurring costs for business development, regulatory filings, and product launch activities. Conversely, professional fees in Q1 2025 ($16,519) were lower than the $44,555 spent in Q1 2024, when significant legal/accounting work related to the corporate reorganization and asset acquisition was underway.

Overall, CSDX achieved a net profit of $32,067 in the first quarter of 2025, a substantial improvement from essentially break-even results in the same quarter of the prior year (net income was reported as $0 in Q1 2024). The positive first quarter earnings in 2025 were driven by the revenue growth combined with controlled operating expenses. It is worth noting that a portion of Q1 2025 revenue was not yet collected by quarter-end (accounts receivable increased during the quarter), indicating that some sales were on credit terms. As a result, cash flow from operations in the quarter was likely lower than net income, an aspect discussed in the Liquidity section below. Nevertheless, the Q1 2025 profitability underscores management's focus on reaching a sustainable cost-revenue balance even at this early stage. Given CSDX's developmental status, quarterly results may fluctuate and may not yet reflect the full revenue potential of its flagship products. The Company expects future periods to be significantly influenced by the commercial rollout of CS Protect-Hydrogel (pending regulatory approval) and the ramp-up of MEDUSA sales, which were only just beginning in Q1 2025.

31 www.csdcorp.us

**Liquidity and Capital Resources**

**Capital Structure and Cash Position**

CSDX's financial condition at year-end 2024 reflects a company that has acquired a major intangible asset but has very limited liquidity. As of December 31, 2024, the Company's balance sheet shows total assets of approximately $499.4 million, almost entirely consisting of the CS Protect-Hydrogel intangible asset valued at $499.4 million, with only $501 in cash on hand. By March 31, 2025, cash had increased to $51,386 (unaudited) as the Company received some funds from operations or small financing activities during Q1. Current assets at March 31, 2025 were $106,112, including cash and new accounts receivable of about $54,726, while current liabilities were $74,931 (primarily accounts payable and accruals). The working capital position remains strained – current liabilities slightly exceeded current assets at Q1's end, and the cash on hand is minimal relative to the Company's needs for product development and launch. CSDX has essentially no long-term debt as of Q1 2025, and total liabilities are very low (only ~$75K). However, stockholders' equity is dominated by the large intangible asset value offset by a corresponding amount recorded in additional paid-in capital. The Company's shareholders' deficit was about $499.4 million at year-end 2024, reflecting the recognition of the hydrogel asset and the equity issued for its purchase. The accumulated deficit stood at $(4.77) million at December 31, 2024, only slightly improved to $(4.74) million by March 31, 2025 due to the small profits earned in late 2024 and Q1 2025. This deficit is the result of prior years' losses, as the Company is only now moving toward profitability on a very small scale.

**Cash Burn and Going Concern**

The Company's historical operations have been funded by equity infusions from its shareholders/parent group rather than by sustainable cash flows. Net cash used in operating activities has likely continued in early 2025 given ongoing expenses and the need to build inventory and infrastructure for product launches. The going concern note in the 2024 financial statements emphasizes that the Company's ability to continue as a going concern is dependent on improving profitability and obtaining financial support from shareholders or other external financing. Management acknowledges that additional capital will be required for the planned operational activities and that there is uncertainty regarding the ability to raise such capital. These conditions raise substantial doubt about CSDX's ability to continue as a going concern absent new funding. The Company's strategy to address this includes seeking external financing and leveraging the value of its assets to secure investment.

**Financing Plans**

CSDX recognizes that its current liquidity is limited thus, the Company took steps to bolster its capital resources. To address this need, the Company has authorized a private placement financing under Rule 506(c) of Regulation D of the Securities Act of 1933, as amended, intended to be offered solely to accredited investors. The Company seeks to raise up to $10 million, with a minimum target of $5 million.

If the Company is successful in raising the $5 million minimum, it intends to allocate the net proceeds approximately as follows:

&nbsp;&nbsp;&nbsp;&nbsp;· U.S. based manufacturing
 – establish production capacity for the CS Protect-Hydrogel product in anticipation
 of regulatory approval and commercialization in the United States;

&nbsp;&nbsp;&nbsp;&nbsp;· Research and development
 – support additional clinical and product development activities for CS Protect-Hydrogel
 and other pipeline products;

&nbsp;&nbsp;&nbsp;&nbsp;· Operational expansion
 – fund staffing, business development, and general corporate infrastructure to support
 growth; and

&nbsp;&nbsp;&nbsp;&nbsp;· Regulatory activities
 – cover costs of license applications, approvals, and related regulatory filings in
 the United States and other jurisdictions.

This offering will not be filed and neither of the securities being offered will be registered with the Securities and Exchange Commission. Instead, the Company will file a Form D notice within 15 days after the first sale of securities in the offering.

The ability to complete the financing on acceptable terms, or at all, remains uncertain. Failure to raise the minimum target keeps the Company reliant on interim support from its major shareholders for meeting obligations and would require the Company to scale back or delay its planned activities, including U.S. manufacturing and regulatory initiatives.

32 www.csdcorp.us

**Capital Expenditures and Requirements**

CSDX currently has no significant capital expenditures disclosed for 2024, as it does not yet have large-scale manufacturing facilities of its own (the hydrogel production for initial markets may be handled through partners or existing capacity of the CS Diagnostics Group). However, in preparation for commercial launch, the Company will likely need to invest in production tooling, inventory build-up, and distribution capabilities, particularly as it approaches the U.S. market entry by 2026. The Company's ability to raise additional capital through equity is evidenced by its prior issuances: in late 2023, it issued 110 million shares (valued at $500 million) to acquire the hydrogel IP, and it has the option to issue more shares if needed (authorized common stock is 250 million shares). Potential future equity issuances could, however, result in dilution to existing shareholders. Besides equity financing, management may also explore strategic partnerships or licensing arrangements to share the costs of commercialization. At this time, the Company has no off-balance sheet arrangements or significant contractual obligations aside from standard accounts payable and the pending financing agreement.

In summary, CSDX's liquidity position is presently very tight, but management has taken steps to secure needed capital. Successful consummation of the planned $5 million financing (or similar funding) is essential for the Company to fund its operations over the next 12-18 months, including completing regulatory approval processes and initiating product sales at scale. If such financing were to be delayed or fail to close, the Company would need to rely on further shareholder loans or curtail its activities. Management believes that the value of its core technology and the size of the market opportunities will ultimately enable the Company to obtain sufficient capital to execute its plans, but it recognizes the need to demonstrate progress (such as obtaining FDA approval and initial revenues) to maintain investor support. The Company will continue to monitor its cash flow closely and will update its capital plan as needed to ensure it can meet its short-term liabilities and invest in growth initiatives.

**Critical Accounting Estimates and Judgments**

The preparation of CSDX's financial statements in accordance with U.S. GAAP requires management to make certain estimates and judgments that have a significant impact on reported results and financial position. The Company's most critical accounting estimate at this stage revolves around the valuation and potential amortization or impairment of the CS Protect-Hydrogel intangible asset. This intangible asset is carried at approximately $499.4 million on the balance sheet, reflecting the value assigned to the acquired product technology and intellectual property. Management recorded this asset based on the fair value of consideration given – 110,000,000 shares of common stock issued in September 2023 – which was determined by reference to a third-party valuation of the hydrogel's discounted future commercial potential (over €960 million) and a benchmark transaction (Boston Scientific's 2018 purchase of a similar spacer product for $500 million). This valuation approach embodies significant judgments about the hydrogel's future revenue, market adoption, and cash flow generation. No amortization expense has been recorded on the hydrogel intangible through 2024, suggesting that management may consider this asset to have an indefinite life at present (or that amortization will commence once the product is fully commercialized). This treatment is a critical judgment; if the hydrogel is deemed to have a finite life (for example, tied to patent expirations or a product lifecycle), the Company would need to amortize the $499 million asset over its useful life, which would greatly increase annual expenses and could quickly eliminate any accounting profits. Management will need to continually evaluate the appropriate useful life and amortization method for this asset as commercialization progresses.

33 www.csdcorp.us

Impairment considerations: Given the Company's lack of substantial revenue to date and the early stage of product approval, there is inherent uncertainty as to whether the hydrogel asset will ultimately generate cash flows to support its carrying value. Management performs impairment analyses as part of its critical accounting judgments. If facts and circumstances (such as a significant delay in FDA approval, lower-than-expected market demand, or inability to secure commercialization funding) indicate that the hydrogel asset's carrying amount may not be recoverable, the Company would conduct an interim impairment test. Any impairment charge could be material, as the $499.4 million intangible constitutes virtually the entire asset base of CSDX. Investors should understand that a write-down of this asset, if required, would severely impact the Company's reported equity and could reclassify the Company as a development stage entity with negative net worth. Management believes the recorded value is supported by external data (e.g., the precedent acquisition by Boston Scientific) and the broad potential applications of the CS Protect-Hydrogel technology, but it acknowledges that this is a key area of estimation uncertainty.

**Other areas of significant accounting judgment include:**

&nbsp;&nbsp;&nbsp;&nbsp;· Going Concern Assessment: As discussed in the Liquidity section, management must evaluate whether the Company can continue as a going
concern for the next 12 months. This involves judgment about future financing and revenue. While the 2024 financials were prepared on
a going concern basis, substantial doubt was disclosed, and management's plans to alleviate that doubt (through financing and improving
profitability) were outlined. This assessment is revisited in each reporting period.

&nbsp;&nbsp;&nbsp;&nbsp;· Deferred Tax Assets: The Company has accumulated losses (approximately $4.7 million deficit) that could give rise to deferred tax
assets. However, given the Company's short operating history in its new line of business and uncertainty about future taxable income,
management has likely determined that a full valuation allowance is necessary. This means no deferred tax asset is recognized on the balance
sheet for net operating loss carryforwards, since it is not "more likely than not" that such **assets would be realized.** This judgment affects the tax expense and will be revisited if the Company begins generating substantial taxable profits.

&nbsp;&nbsp;&nbsp;&nbsp;· Revenue Recognition: While current revenues are small, management must ensure proper cut-off and recognition of any service or product
revenues. For example, any distribution or consulting service revenue is recognized when earned, and any product sales will be recognized
upon delivery of product to customers (assuming no further performance obligations). Given that some Q1 2025 sales were on credit, the
Company also evaluates collectability. To date, revenue recognition has not involved complex arrangements, but as product sales grow (especially
with MEDUSA and potentially hydrogel in multiple markets), management will need to consider any licensing deals, consignment arrangements,
or usage-based pricing which could introduce more complexity.

&nbsp;&nbsp;&nbsp;&nbsp;· Stock-Based Transactions: The Company's issuance of shares for asset acquisition and any future equity financing (such as the
Series C Preferred proposed issuance) are accounted for at fair value. Management relies on valuation techniques to determine fair value
of shares, especially since the stock is thinly traded. Any discrepancy in these estimates would affect additional paid-in capital and
could have tax implications for the parties involved.

Management believes that the above critical accounting estimates are based on reasonable assumptions and consistently applied. However, actual results could differ from these estimates, and changes in assumptions or market conditions could require adjustments to carrying values or recognition of additional expenses in future periods. The Company's audit for 2024 resulted in an unqualified opinion with no critical audit matters identified beyond the going concern emphasis, indicating that the external auditors concurred with management's accounting treatments and estimates as of that time.

**Known Trends, Events, and Uncertainties**

As CSDX moves beyond its restructuring phase and into active commercialization, several key trends, events, and uncertainties are likely to influence its financial condition and operations:

34 www.csdcorp.us

**Regulatory Approval and Commercialization Timeline**

The Company's flagship product candidate, CS Protect-Hydrogel, is regulated as a medical device and will require marketing authorization from the U.S. Food and Drug Administration ("FDA") before it can be marketed in the United States. Regulatory clearance is not guaranteed and the length of the review process is inherently uncertain. Management has engaged experienced FDA regulatory consultants to assist with preparation of the necessary submissions. However, the timing, scope, and outcome of the FDA review are solely within the authority of the FDA and cannot be predicted with certainty. Approval, if obtained, may require additional clinical data, modifications to our submissions, or extended review periods.

In parallel, the product will require regulatory registration in other jurisdictions, such as CE certification through the German Federal Institute for Drugs and Medical Devices (BfArM) under the European Medical Device Regulation. Each jurisdiction has its own regulatory process and timeline. Multiple separate approvals may also be necessary for different cancer indications (e.g., prostate, cervical, esophageal, bladder, and breast cancers).

With respect to MEDUSA, our surface disinfectant, regulatory approvals are required from environmental or public health authorities (for example, the U.S. Environmental Protection Agency ("EPA") for marketing in the United States). Approvals may also be required in other jurisdictions.

Given the inherent uncertainty of these processes, there can be no assurance that regulatory clearance for CS Protect-Hydrogel or MEDUSA will be obtained in a timely manner, or at all. Investors are urged to review the sections entitled "Risk Factors—Regulatory Approval and Compliance Risks" and "Known Trends, Events, and Uncertainties—Regulatory Approval and Commercialization Timeline" for additional information regarding the risks associated with regulatory approval.

The foremost near-term event for the Company is obtaining U.S. FDA approval for CS Protect-Hydrogel. Management has been fast-tracking this process by engaging experienced FDA regulatory consultants (Lachman Consultants) and, as of March 12, 2025, anticipated FDA clearance of the hydrogel within 3–4 months from that date. If this timeline holds, the Company could receive approval by mid-2025, which would be a catalyst for initiating sales in the U.S. market. Any delay or unexpected requirement from the FDA would be a significant uncertainty – regulatory processes can be unpredictable, and the Company may need to conduct additional clinical studies or provide more data, which could postpone commercialization. In parallel with U.S. efforts, the product will also require regulatory registration in other jurisdictions. The Company's background in navigating European and MENA regulatory environments should be advantageous in obtaining approvals in those markets; however, timelines for CE marking under Europe's MDR or other local approvals are not explicitly disclosed and remain an uncertainty.

**Product Launch and Manufacturing**

CSDX is preparing for the scale-up of production for CS Protect-Hydrogel. The Company projects that U.S. production will commence by the first quarter of 2026, aligning with expected market approval and the need to ramp manufacturing capacity. This suggests that 2025 will be focused on setting up manufacturing processes (potentially tech-transfer to a U.S. manufacturing site or contract manufacturer) and securing supply chain logistics. There is a known trend in the medtech industry of supply chain challenges and costs inflation, so the Company will need to manage raw material sourcing for the hydrogel and sterile packaging in a cost-effective manner. The ability to meet production timelines by Q1 2026 is crucial; any operational hurdles or delays in facility readiness could impact the product launch schedule. Management's decision to pursue an equity funding (the $5M loan agreement) in 2025 is directly tied to financing these manufacturing and launch activities. Investors should monitor the progress of production preparations in late 2025, as this will indicate whether the Company is on track to fulfill its projected timeline.

35 www.csdcorp.us

**Market Adoption and Competition**

Upon entering the market, CS Protect-Hydrogel will face competition from at least one well-established product. Boston Scientific's SpaceOAR hydrogel (acquired from Augmenix) is currently the leading tissue spacer for prostate cancer radiotherapy and has an installed base of users. While CS Protect-Hydrogel is positioned as a next-generation spacer with broader applications, it may initially compete directly with SpaceOAR in the prostate cancer segment. Boston Scientific's resources and relationships with hospitals could pose a competitive challenge. CSDX's strategy is to differentiate CS Protect-Hydrogel through its enhanced features – notably, its versatility to be used in multiple cancer types (beyond just prostate) and its ready-to-use formulation that requires no mixing or prep work in the operating room. These competitive advantages, such as eliminating contamination risk and preventing potential errors in preparation, will be key selling points to drive adoption by radiation oncologists and urologists. Market acceptance is a potential uncertainty; the medical community will need to be educated on the hydrogel's benefits, and CSDX may need to sponsor additional clinical studies or publish data demonstrating improved outcomes (e.g. reduced side effects or the ability to safely escalate radiation doses). The broader trend in oncology toward hypofractionation (fewer, higher-dose treatments) could work in the Company's favor – a spacer that reliably protects healthy tissue can enable such treatment protocols. If CS Protect-Hydrogel can facilitate safer hypo fractionated radiotherapy, it could accelerate adoption in modern cancer care settings**.**

**Commercial Potential vs. Risks**

The market potential for CS Protect-Hydrogel is significant, as indicated by the valuation references: management often notes that a predecessor product was bought for $500 million, underscoring the high value placed on effective spacer technologies in radiation oncology. Moreover, by expanding the indications to other cancers (e.g. gynecological or gastrointestinal cancers where organ spacing can prevent collateral damage), CSDX aims to tap into multiple therapy markets. If successful, the hydrogel could generate substantial revenue streams across different oncology subfields. However, this potential comes with execution risks. The Company is still small and will need to form distribution partnerships or build a salesforce to reach hospitals and clinics globally. Establishing relationships with key opinion leaders in radiation oncology is crucial for driving adoption. There is also the risk of new entrants or technologies: for instance, other biotech companies might develop alternative spacer materials or completely different solutions (such as protective pharmaceuticals or advanced radiation techniques that mitigate the need for spacers). CSDX must continuously innovate and protect its intellectual property; fortunately, the Company acquired all patents and distribution rights for CS Protect-Hydrogel from the former parent group, which should provide some moat against direct product copycats in the near term. Another risk to the commercial potential is reimbursement – insurance coverage in the U.S. and elsewhere will influence how readily hospitals adopt the hydrogel. SpaceOAR, for example, obtained specific reimbursement codes; CSDX will need to ensure similar coverage, otherwise the out-of-pocket cost to patients could limit usage.

**Diversification and Other Products**

A notable development during the firsts quarter of 2025 was the launch of the MEDUSA disinfectant product. This reflects a diversification of the Company's activities to include infection control products in addition to therapeutic devices. MEDUSA's commercialization is at an early stage, and its future market acceptance, sales levels, and regulatory outcomes remain uncertain. Management has articulated internal objectives for MEDUSA that, if achieved, could expand the scale of the Company's operations; however, there can be no assurance that these objectives will be realized in whole or in part.

The Company has also explored brand-building initiatives to support MEDUSA, including preliminary discussions with a major European football club regarding potential sponsorship opportunities. Those negotiations have since been halted, and management does not intend to pursue such opportunities until the Company receives regulatory clearance in the United States to market MEDUSA.

36 www.csdcorp.us

MEDUSA presents a distinct regulatory and commercial profile compared to CS Protect-Hydrogel. Whereas CS Protect-Hydrogel is regulated as a medical device subject to FDA clearance and specialist marketing, MEDUSA requires approval by the Environmental Protection Agency in the United States and competes in a broader consumer and institutional disinfectant market with numerous established manufacturers. The extent to which the Company can successfully balance resources between these two product lines, and the timing of any regulatory approvals, remain important uncertainties for investors to consider.

**Management and Organizational Changes**

Another development in late 2024 was changes to the Company's board and executive team. In August 2024, new directors and officers were appointed, including a Vice President/CFO and additional independent directors, while some prior directors stepped down. These changes brought in individuals with specific expertise (the presence of a COO with medtech experience, and presumably the new board members with industry connections). Such changes can impact the Company's strategic direction and operational execution. Early 2025 actions, such as the financing LOI and product launches, suggest the new management is proactive. However, the Company's ability to grow will also depend on hiring qualified staff (for R&D, regulatory affairs, sales etc.), and competition for talent in the biotech and medtech field is a known challenge. CSDX will likely need to expand its team as it enters commercialization, which could increase expenses in the short term.

**Macroeconomic and Market Conditions**

CSDX operates in the healthcare sector, which is generally less cyclical than other industries, but it is not immune to broader economic conditions. Inflationary pressures could increase the cost of raw materials for the hydrogel or components for packaging. Currency fluctuations may also affect the Company since part of its operations (and potentially manufacturing or parent company support) is in Europe – the valuation of the hydrogel was initially done in euros and then translated to USD. If the dollar/euro rate changes significantly, it could impact cost structures or the perceived value of overseas funding. Additionally, capital market conditions in 2025 will determine how easily the Company can raise further equity. Micro-cap public companies can face volatile trading and difficult financing environments if investor sentiment turns negative. The OTCQB listing provides a platform, but ultimately CSDX may seek an uplist to a national exchange to access a broader pool of investors – such ambitions would depend on meeting certain financial and governance criteria, which remain a longer-term consideration.

**Conclusion**

The path forward for CS Diagnostics Corp. presents opportunities as well as significant uncertainties. The Company is in the process of developing CS Protect-Hydrogel, which it believes may represent a novel approach in the medical device space, along with MEDUSA, a long-acting disinfection product. Neither product has received marketing authorization in the United States, and there can be no assurance that regulatory approval will be obtained in a timely manner, or at all.

Like many emerging growth companies, CS Diagnostics faces challenges including obtaining required regulatory approvals, scaling up manufacturing and sales, securing adequate financing, and competing with established industry participants, all while transitioning into an SEC-reporting company subject to enhanced disclosure and compliance requirements. Management has prepared forward-looking statements regarding potential future milestones, such as possible FDA approval of CS Protect-Hydrogel, anticipated timelines for U.S. production, and potential revenue generation. These statements reflect management's current plans and observations, but are inherently subject to numerous risks and uncertainties.

37 www.csdcorp.us

Actual results may differ materially from management's expectations due to factors such as the timing and outcome of regulatory processes, competitive dynamics, availability of capital, and the Company's ability to execute its commercialization strategy. Investors should carefully review the risk factors and uncertainties described in this filing when evaluating the Company's prospects.

**Going forward**

CS Diagnostics Corp. intends to continuously update stakeholders on its progress. The Company's management remains confident that by focusing on its core strengths – innovative product development, regulatory expertise, and strategic partnerships – it can navigate the upcoming challenges and build a sustainable, high-growth business that delivers long-term shareholder value. The remainder of 2025 will be a crucial period for executing on its milestones (FDA approval, financing closure, initial market launches), and the Company's financial health and operational results will hinge on the successful realization of these plans. All forward-looking statements in this MD&A are made as of the current date and are subject to the safe harbor provisions; actual outcomes will be reported in future filings, and management undertakes to update its guidance as appropriate in light of new information or changes in circumstances.

**LEGAL PROCEEDINGS**

From time to time, we may become involved in various legal or administrative claims and proceedings arising in the ordinary course of business.

In early 2025, following a decline in the Company's stock price from approximately $3.00 per share in late 2024 to sub-penny levels, the Company discovered that a minority shareholder had sold a significant volume of CSDX stock despite having previously indicated a long-term investment intent. Management sought to reach a voluntary arrangement with the shareholder to mitigate market disruption, but the shareholder continued selling. The Company believes these actions contributed to a loss of investor confidence and impaired relationships with potential investors and service providers.

As a result, the Company filed a civil action in the United States District Court for the Northern District of Texas, captioned CS Diagnostics Corp. v. Wilson, Case No. 3:25-cv-01158-N, seeking damages and equitable remedies.

This matter has also affected the Company's ability to pursue its objective of meeting the listing standards of a national securities exchange in 2025. The Company emphasizes that it does not seek to restrict shareholders from selling their securities, but rather to promote orderly market activity and protect the interests of all investors.

38 www.csdcorp.us

**INDEX TO FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| **CS Diagnostics, Corp. Unaudited Interim Financial Statement (period ending March 31, 2025)** |  |
| Balance Sheets as of March 31, 2025, and December 31, 2024 | **F-2** |
| Statements of Operations for the Three months period ended March 31, 2025, and March 31, 2024 | **F-3** |
| Statements of Stockholders' Equity for Three months period ended March 31, 2025, and March 31, 2024 | **F-4** |
| Statements of Cash Flows for Three months period ended March 31, 2025, and March 31, 2024 | **F-5** |
| Notes to the Financial Statements | **F-6** |
| **CS Diagnostics, Corp. Financial Statement (period ending December 31, 2024 and December 31, 2023)** |  |
| Report of Independent Registered Public Accounting Firm | **F-10** |
| Balance Sheets as of December 31, 2024, and December 31, 2023 | **F-11** |
| Statements of Operations for the twelve months period ended December 31, 2024, and December 31, 2023 | **F-12** |
| Statements of Stockholders' Equity for twelve months period ended December 31, 2024, and December 31, 2023 | **F-13** |
| Statements of Cash Flows for the twelve months period ended December 31, 2024, and December 31, 2023 | **F-14** |
| Notes to the Financial Statements | **F-15** |

---

F-1 www.csdcorp.us

---

| |
|:---|
| **CS DIAGNOSTICS CORP. (CSDX)** |
| **BALANCE SHEET** |
| **FOR THE PERIOD ENDED MARCH 31, 2025** |

---

---

| | | |
|:---|:---|:---|
|  | Mar. 31, 2025 | Dec. 31, 2024 |
|  | *Un-Audited* | *Audited* |
| *<u>Assets</u>* |  |  |
| **Current Assets** |  |  |
| Cash | 51386 | 501 |
| Other Receivables | 54726 |  |
| **Total Current Assets**  | $**106112** | $**501** |
| Intangible Assets | 499400000 | 499400000 |
| **Total Assets**  | $**499506112** | $**499400501** |
| *<u>Liabilities and Stockholders' Deficit</u>* |  |  |
| **Current Liabilities** |  |  |
| Account Payables | 2931 | 1428 |
| Non-current liabilities | 0 | 0 |
| **Total Liabilities**<br>| **74931** | **1428** |
| **Shareholder's Deficit** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.00001 par value; 250,000,000 shares<br> authorized 137,340,200 shares issued and outstanding as of March 31, 2025 | 1373 | 1373 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock Series A, $0.00001 par value;5,000 shares authorized, 10<br> shares issued and outstanding as of March 31, 2025 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock Series B, $0.00001 par value; 20,000,000 shares authorized,<br> 19,992,575 shares issued and outstanding as of March 31, 2025 | 2000 | 2000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock Series C, $0.00001 par value; 4,000,000 shares authorized, 0<br> shares issued and outstanding as of March 31, 2025 | 40 |  |
| Additional paid-in capital | 504163629 | 504163629 |
| Accumulated deficit | (4735861) | (4767928) |
| **Total Stockholders' Deficit** | $**499431181** | $**499399073** |
| **Total Liabilities and Stockholders' Deficit** | $**499506112** | $**499400501** |

---

*The accompanying notes are an integral part of these financial statements.*

*This is an unaudited financial statement, can be subject to minor changes upon Auditor review*

F-2 www.csdcorp.us

---

| |
|:---|
| **CS DIAGNOSTICS CORP. (CSDX)** |
| **STATEMENT OF OPERATIONS** |
| **FOR THE PERIOD ENDED MARCH 31, 2025** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31<sup>st</sup>** | **For the Three Months Ended March 31<sup>st</sup>** |
|  | **2025** | **2024** |
| Revenue | 70420 | 53258 |
| **Revenue** | $**70420** | $**53258** |
| *Operating Expenses* |  |  |
| Professional Fee | 16519 | 44555 |
| General & Administrative Expenses | 21834 | 140 |
| Total Operating Expenses | 38353 | 8564 |
| **Income/(loss) from Operations** | $**32067** | $**8564** |
| Other Income / (Expense) |  |  |
| Debt Written off |  |  |
| Net Income / (loss) | $32067 | $0.00 |
| Basic and diluted loss per share | 0.00 | 0.00 |
| **basic and diluted loss weighted average shares** | **137340200** | **110790200** |

---

*The accompanying notes are an integral part of these financial statements.*

*This is an unaudited financial statement, can be subject to minor changes upon Auditor review*

F-3 www.csdcorp.us

---

| |
|:---|
| **CS DIAGNOSTICS CORP. (CSDX)** |
| **STATEMENT OF STOCKHOLDERS (DEFICIT)** |
| **FOR THE PERIOD ENDED MARCH 31, 2025** |

---

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock B** | **Preferred Stock B** | **Preferred Stock C** | **Preferred Stock C** | **Common Stock** | **Common Stock** | **Additional** | **Accumulated** | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Paid-in Capital** | **Deficit** | **Total** |
| Balance, January 1, 2024 | 20000000 | $2000 | $0 | $0 | 110790200 | $1018 | $504173122 | $(4798689) | $449407450 |
| Reversed Stock Split |  |  |  |  |  |  |  |  |  |
| Shares Issued/Converted | (1325) | $0 | $0 | $0 | 26500000 | $355 | $(9493) |  | $(9138) |
| Net income (loss) for the year |  |  |  |  |  |  |  | $761 | $761 |
| **Balance, December 31, 2024** | **19998675** | $**2000** | $**0** | $**0** | **137290200** | $**1373** | $**504163629** | $**(4767928)** | $**449399073** |
| Balance, January 1st, 2025 | 19998675 | 2000 | 0 | 0 | 137290200 | 1373 | 504163629 | (4767928) | 449399073 |
| Shares Issued/Converted | (6100) |  | 4000000 | $40 | 50000 |  |  |  |  |
| Net income (loss) for the <br> period ended March 31, 2025 |  |  |  |  |  |  |  | $32067 | $32067 |
| Shares Issued in acquisition of <br> Assets |  |  |  |  |  |  |  |  |  |
| **Balance, March 31, 2025** | **19992575** | **2000** | **4000000** | $**40** | **137340200** | **1373** | **504163629** | **(4767928)** | **449431181** |

---

*The accompanying notes are an integral part of these financial statements.*

*This is an unaudited financial statement, can be subject to minor changes upon Auditor review*

F-4 www.csdcorp.us

---

| |
|:---|
| **CS DIAGNOSTICS CORP. (CSDX)** |
| **STATEMENT OF CASH FLOWS** |
| **FOR THE PERIOD ENDED MARCH 31, 2025** |

---

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31<sup>st</sup>** | **For the Three Months Ended March 31<sup>st</sup>** |
|  | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Net profit/ (loss) | 32067 | 8564 |
| Adjustment to reconcile net loss to net cash used in operating activities |  |  |
| Changes in assets and liabilities |  |  |
| Other Receivables | 21750 |  |
| Account payables | (2931) | (11248) |
| **Net cash used in operating activities** | $**50886** | $**(2684)** |
| **Cash flows from investing activities** |  |  |
| Intangible Asset | (499444401) |  |
| **Net cash provided by Investing activities** | $**(499444401)** | **-** |
| **Cash flows from financing activities** |  |  |
| Additional Capital Paid Up | 499444401 |  |
| Loan forgiven |  |  |
| **Net cash provided by financing activities** | $**499444401.00** | **-** |
| Net increase /(decrease) in cash | **50886** | (2684) |
| Cash beginning of period | **501** | 20363 |
| **Cash end of period** | $**51386** | $**17679** |

---

*The accompanying notes are an integral part of these financial statements.*

*This is an unaudited financial statement, can be subject to minor changes upon Auditor review*

F-5 www.csdcorp.us

**CS DIAGNOSTICS, CORP.**

**Notes to Financial Statements**

**March 31, 2025, and December 31, 2024**

**NOTE 1- ORGANIZATION AND DESCRIPTION OF BUSINESS**

**CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics Corp., is an United States based Corporation, Its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology.**

On August 1, 2023, FINRA authorized the Corporate Action approved by the Board of Directors and majority shareholder for and amendment to the Articles of Incorporation from FlashZero Corp to CS Diagnostics Corp and a 1 for 100,000 reverse split followed by a 200 for 1 forward split and a change of the CUSIP to 33852L202. Pre-split shares: 135,287,214: Post Split share 790,200.

On September 4, 2023, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS ProtectHydrogel is a hydrogel- based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*<u>Basis of Presentation</u>*

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

*<u>Use of Estimates</u>*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

*<u>Concentrations of Credit Risk</u>*

Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount.

F-6 www.csdcorp.us

*<u>Cash and Cash Equivalents</u>*

The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended March 31, 2024, and 2023.

*<u>Fair Value of Financial Instruments</u>*

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below:

Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates.

Level 3: Level 3 inputs are unobservable inputs.

The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values.

The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates.

*<u>Income Taxes</u>*

We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date.

F-7 www.csdcorp.us

We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25.

*<u>Net income (loss) per common share</u>*

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the period ended March 31, 2025 and 2024, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti- dilution due to the net loss incurred by the Company

*<u>Recent Accounting Pronouncements</u>*

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

**NOTE 3 – GOING CONCERN**

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,760,125) at March 31, 2024. The continuation of the Company as a going concern through March 31, 2024, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.

The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

**NOTE 4 – INCOME TAXES**

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used.

F-8 www.csdcorp.us

Net deferred tax assets consist of the following components as of:

---

| | | |
|:---|:---|:---|
|  | **March**<br> **31, 2025** | **December**<br> **31, 2024** |
| &nbsp;&nbsp;**Federal income tax benefit attributable to:** |  |  |
| &nbsp;&nbsp;**Current Operations** | $— | $— |
| &nbsp;&nbsp;**Less: valuation allowance** |  |  |
| &nbsp;&nbsp;**Net provision for Federal income taxes** | $— | $— |

---

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following:

---

| | | |
|:---|:---|:---|
|  | **March**<br> **31, 2025** | **December**<br> **31, 2024** |
| &nbsp;&nbsp;**Deferred tax asset attributable to:** |  |  |
| &nbsp;&nbsp;**Net operating loss carryover** | $— | $— |
| &nbsp;&nbsp;**Less: valuation allowance** |  |  |
| &nbsp;&nbsp;**Net deferred tax asset** | $— | $— |

---

At March 31, 2025, the Company had net operating loss carry forwards of approximately $(4,735,861) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported in the March 31 2025, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015.

**NOTE 5 – SUBSEQUENT EVENTS**

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.

F-9 www.csdcorp.us

AUDIT & TAX CONSULTANT

![](laoprofessionals_logo.jpg)

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

**To the Board of Directors and Stockholders of CS Diagnostic Corp**

<u>Opinion on the Financial Statements</u>

We have audited the accompanying balance sheets of CS Diagnostic Corp. (the 'Company') as of December 31, 2024, and the related statements of operations, changes in stockholders' equity and cash flows for the year ended December 31, 2024, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

<u>Going Concern</u>

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3, the Company suffered an accumulated deficit of $(4,767,928). These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's plans with regards to these matters are also described in Note 3 to the financial statements. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

<u>Basis for Opinion</u>

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

<u>Critical Audit Matters</u>

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. Communication of critical audit matters does not alter in any way our opinion on the financial statements taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

/S/ Lateef Awojobi

**LAO PROFESSIONALS**

(PCAOB ID 7057)

Lagos, Nigeria

We have served as the Company's auditor since 2025. April 14, 2025

F-10 www.csdcorp.us

---

| |
|:---|
| **CS DIAGNOSTICS CORP. (CSDX)** |
| **BALANCE SHEET** |
| **FOR THE PERIOD ENDED DECEMBER 31, 2024** |

---

---

| | | |
|:---|:---|:---|
|  | Dec. 31, 2024 | Dec. 31, 2023 |
|  | *Audited* | *Audited* |
| *<u>Assets</u>* |  |  |
| **Current Assets** |  |  |
| Cash | 501 | 20363 |
| Other Receivables |  |  |
| **Total Current Assets** | $**501** | $**20363** |
| Intangible Assets | 499400000 | 499400000 |
| **Total Assets** | $**499400501** | $**499420363** |
| *<u>Liabilities and Stockholders' Deficit</u>* |  |  |
| **Current Liabilities** |  |  |
| Account Payables | 1428 | 12822 |
| Non-current liabilities |  |  |
| **Total Liabilities** | $**1428** | $**12822** |
| **Shareholder's Deficit** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.00001 par value; 250,000,000 shares<br> authorized 137,290,200 shares issued and outstanding as of December 31, 2024 | 1373 | 1108 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock Series A, $0.001 par value;5,000 shares authorized, 10<br> shares issued and outstanding as of December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock Series B, $0.001 par value; 19,998,675 shares authorized,<br> 19,999,375 shares issued and outstanding as of December 31, 2024 | 2000 | 2000 |
| Additional paid-in capital | 504163629 | 504173122 |
| Accumulated deficit | (4767928) | (4768689) |
| **Total Stockholders' Deficit** | $**499399073** | $**499407541** |
| **Total Liabilities and Stockholders' Deficit** | $**499400501** | $**499420363** |

---

*The accompanying notes are integral part of these financial statements.*

F-11 www.csdcorp.us

---

| |
|:---|
| **CS DIAGNOSTICS CORP. (CSDX)** |
| **STATEMENT OF OPERATIONS** |
| **FOR THE PERIOD ENDED DECEMBER 31, 2024** |

---

---

| | | |
|:---|:---|:---|
|  | **December 31, 2024** | **December 31, 2023** |
| Revenue | 110911 | 126038 |
| **Revenue** | $**110910.60** | $**126038** |
| *Operating Expenses* |  |  |
| Professional Fee | 109755 | 54026 |
| General & Administrative Expenses | 395 | 94009 |
| Total Operating Expenses | 110150 | 148035 |
| **Income/(loss) from Operations** | $**761** | $**(21997)** |
| Other Income / (Expense) |  |  |
| Debt Written off |  |  |
| Net Income / (loss) | $761 | $(21997) |
| Basic and diluted loss per share | 0.00 | 0.00 |
| **basic and diluted loss weighted average shares** | **137290200** | **110790200** |

---

 

*The accompanying notes are an integral part of these financial statements.*

F-12 www.csdcorp.us

---

| |
|:---|
| **CS DIAGNOSTICS CORP. (CSDX)** |
| **STATEMENT OF STOCKHOLDERS (DEFICIT)** |
| **FOR THE PERIOD ENDED DECEMBER 31, 2024** |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Preferred Stock B** | **Preferred Stock B** | **Common Stock** | **Common Stock** | **Additional** | **Accumulated** | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Paid-in Capital** | **Deficit** | **Total** |
| Balance, January 1, 2023 | 20000000 | $2000 | 135287214 | $1352 | $4712037 | $(4746692) | $(31303) |
| Reversed Stock Split |  |  | (134497014) | $(1344) |  |  | $(1344) |
| Shares Issued in <br> acquisition of Assets |  |  | 110000000 | $1100 | $499461085 |  | $499462185 |
| Net income (loss) for the year |  |  |  |  |  | $(21997) | $(21997) |
| **Balance, December 31, 2023** | **19998675** | $**2000** | **110790200** | $**1108** | $**504173122** | $**(4768689)** | $**499407541** |
| Balance, January 1, 2024 | 20000000 | 2000 | 110790200 | $1108 | $504173122 | $(4798689) | $499407451 |
| Shares Issued/Converted | (1325) | $0 | 26500000 | $355 | $(9493) |  | $(9138) |
| Net income (loss) for the <br> period ended September 30, 2024 |  |  |  |  |  | $761 | $761 |
| Shares Issued in <br> acquisition of Assets |  |  |  |  |  |  |  |
| **Balance, December 31, 2024** | **19998675** | **2000** | **137290200** | $**1373** | $**504163629** | **(4767928)** | $**499339073** |

---

*The accompanying notes are an integral part of these financial statements.*

 

F-13 www.csdcorp.us

 

---

| |
|:---|
| **CS DIAGNOSTICS CORP. (CSDX)** |
| **STATEMENT OF CASH FLOWS** |
| **FOR THE PERIOD ENDED DECEMBER 31, 2024** |

---

---

| | | |
|:---|:---|:---|
|  | **December 31, 2024** | **December 31, 2023** |
| **Cash flows from operating activities** | | |
| Net profit/ (loss) | 761 | (21997) |
| Adjustment to reconcile net loss to net cash used in operating activities |  |  |
| Changes in assets and liabilities |  |  |
| Other Receivables | 8842 |  |
| Account payables | 1428 | 31285 |
| **Net cash used in operating activities** | $**11030** | $**(9288)** |
| **Cash flows from investing activities** |  |  |
| Intangible Asset | (499444401) | $(499444401) |
| **Net cash provided by Investing activities** | $**(499444401)** | $**(499444401)** |
| **Cash flows from financing activities** |  |  |
| Additional Capital Paid Up | 499444401 | 499422309 |
| Loan forgiven |  |  |
| **Net cash provided by financing activities** | $**499444401.00** | $**(499422309.00)** |
| Net increase /(decrease) in cash | **11030** | (12804) |
| Cash beginning of period | **501** | 12804 |
| **Cash end of period** | $**11030** | $**0** |

---

*The accompanying notes are an integral part of these financial statements.*

F-14 www.csdcorp.us

**CS DIAGNOSTICS, CORP.**

**Notes to Financial Statements**

**December 31, 2024 and December 31, 2023**

**NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS**

**CS Diagnostics Corp., (the "Company") a Wyoming Corporation in the United State, CS Diagnostics Corp., is an United States based Corporation, Its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit. We work hand in hand with universities, experts and experienced users as well as with our users, as well as with our own R&D team, in order to always offer the most innovative products in medical technology.**

On August 1, 2023, FINRA authorized the Corporate Action approved by the Board of Directors and majority shareholder for and amendment to the Articles of Incorporation from FlashZero Corp to CS Diagnostics Corp and a 1 for 100,000 reverse split followed by a 200 for 1 forward split and a change of the CUSIP to 33852L202. Pre-split shares: 135,287,214: Post Split share 790,200.

On September 4, 2023, CS Diagnostics Corp purchased 100% of the tangible product CS Protect-Hydrogel, its intellectual property, distribution rights and patents from the CS Diagnostics Group, headquartered in Germany. The CS ProtectHydrogel is a hydrogel- based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation. Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy. The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months. The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer.

**NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

*<u>Basis of Presentation</u>*

The Company's financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

*<u>Use of Estimates</u>*

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the estimated useful lives of property and equipment. Actual results could differ from those estimates.

*<u>Concentrations of Credit Risk</u>*

Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash and accounts receivable. The Company's cash is deposited with major financial institutions. At times, such deposits may be in excess of the Federal Deposit Insurance Corporation insurable amount.

F-15 www.csdcorp.us

*<u>Cash and Cash Equivalents</u>*

The Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less as cash and cash equivalents. The carrying amount of financial instruments included in cash and cash equivalents approximates fair value because of the short maturities for the instruments held. There were no cash equivalents for the period ended March 31, 2024, and 2023

*<u>Fair Value of Financial Instruments</u>*

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC Topic No. 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels, as described below:

Level 1: Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable, either directly or indirectly. Level 2 inputs include quoted prices for similar assets, quoted prices in markets that are not considered to be active, and observable inputs other than quoted prices such as interest rates.

Level 3: Level 3 inputs are unobservable inputs.

The following required disclosure of the estimated fair value of financial instruments has been determined by the Company using available market information and appropriate valuation methodologies. However, considerable judgment is required to interpret market data to develop the estimates of fair value. Accordingly, the use of different market assumptions and/or estimation methodologies may have a material effect on the estimated fair value amounts.

The methods and assumptions used to estimate the fair values of each class of financial instruments are as follows: Accounts Receivable, and Accounts Payable. The items are generally short-term in nature, and accordingly, the carrying amounts reported on the consolidated balance sheets are reasonable approximations of their fair values.

The carrying amounts of Notes Payable approximate the fair value as the notes bear interest rates that are consistent with current market rates.

*<u>Income Taxes</u>*

We follow ASC 740-10-30, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the fiscal year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the fiscal years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Income in the period that includes the enactment date.

F-16 www.csdcorp.us

We adopted ASC 740-10-25 ("ASC 740-10-25") with regard to uncertainty income taxes. ASC 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10-25, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740-10-25 also provides guidance on derecognition, classification, interest and penalties on income taxes, and accounting in interim periods and requires increased disclosures. We had no material adjustments to our liabilities for unrecognized income tax benefits according to the provisions of ASC 740-10-25.

*<u>Net income (loss) per common share</u>*

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common shares assumes that the Company incorporated as of the beginning of the first period presented. For the period ended March 31, 2024 and 2023, the diluted loss per share is the same as the basic loss per shares as the inclusion of any potentially dilutive shares would result in anti- dilution due to the net loss incurred by the Company

*<u>Recent Accounting Pronouncements</u>*

The Company has implemented all applicable accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

**NOTE 3 – GOING CONCERN**

The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has accumulated deficit of $(4,767,928) at March 31, 2024. The continuation of the Company as a going concern through March 31, 2024, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due.

The Company requires capital for its contemplated operational activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. These conditions and the ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

F-17 www.csdcorp.us

**NOTE 4 – INCOME TAXES**

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss, and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21% is being used.

Net deferred tax assets consist of the following components as of:

---

| | | |
|:---|:---|:---|
|  | **December** <br> **31, 2024** | **December**<br> **31, 2023** |
| &nbsp;&nbsp;**Federal income tax benefit attributable to:** |  |  |
| &nbsp;&nbsp;**Current Operations** | $— | $— |
| &nbsp;&nbsp;**Less: valuation allowance** |  |  |
| &nbsp;&nbsp;**Net provision for Federal income taxes** | $— | $— |

---

The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate to pretax income from continuing operations for the fiscal years ending, due to the following:

---

| | | |
|:---|:---|:---|
|  | **December**<br> **31, 2024** | **December**<br> **31, 2023** |
| &nbsp;&nbsp;**Deferred tax asset attributable to:** |  |  |
| &nbsp;&nbsp;**Net operating loss carryover** | $— | $— |
| &nbsp;&nbsp;**Less: valuation allowance** |  |  |
| &nbsp;&nbsp;**Net deferred tax asset** | $— | $— |

---

At September 30, 2024, the Company had net operating loss carry forwards of approximately $(4,759,589) that may be offset against future taxable income from the year 2022 to 2040. No tax benefit has been reported in the June 30, 2024, financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards for Federal Income tax reporting purposes are subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years. With few exceptions, the Company is no longer subject to U.S. federal, state and local income tax examinations by tax authorities for years before 2015.

**NOTE 5 – SUBSEQUENT EVENTS**

In accordance with SFAS 165 (ASC 855-10) management has performed an evaluation of subsequent events through the date that the financial statements were issued and has identified the following events to disclose in these financial statements.

F-18 www.csdcorp.us